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Review

Monitoring and modelling the dynamics of the
cellular glycolysis pathway: A review and future
perspectives
Nitin Patil 1, 2, *, Orla Howe 3, Paul Cahill 4, Hugh J. Byrne 1
ABSTRACT
Background: The dynamics of the cellular glycolysis pathway underpin cellular function and dysfunction, and therefore ultimately health,
disease, diagnostic and therapeutic strategies. Evolving our understanding of this fundamental process and its dynamics remains critical.
Scope of review: This paper reviews the medical relevance of glycolytic pathway in depth and explores the current state of the art for monitoring
and modelling the dynamics of the process. The future perspectives of label free, vibrational microspectroscopic techniques to overcome the
limitations of the current approaches are considered.
Major conclusions: Vibrational microspectroscopic techniques can potentially operate in the niche area of limitations of other omics technologies for non-destructive, real-time, in vivo label-free monitoring of glycolysis dynamics at a cellular and subcellular level.
Ó 2022 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
Most of the metabolic networks for energy production/nutrient utilisation were elucidated during the ‘golden age of biochemistry’
(roughly 1920se1960s) [1], resulting in around ﬁfteen Noble Prizes
related to energy balance or core metabolic pathways [1]. Glycolysis,
an anaerobic mechanism, is believed to be the ﬁrst ATP production
pathway to evolve, as it is common to both prokaryotes and eukaryotes
[2,3]. It is involved in aerobic and anaerobic energy production,
responsible for production of precursors for other metabolic pathways
and serves as the primary energy source for cells without mitochondria
[4]. The glycolysis process was ﬁrst explored by Louis Pasteur in the
1800s, and it took almost 100 years to fully elucidate the complete
pathway, proposed by Embden, Meyerhof and Parnas in the 1940s [5].
Glycolysis is intricately linked with several human disease mechanisms
and drug toxicities [1,6,7]. It is involved in a multitude of epidemic
diseases such as cancer [8], neurological disorders [9], diabetes [10],
etc., and has attracted substantial attention from scientiﬁc community
for disease diagnostics [11], therapy [12,13], drug targeting [14], etc.
Almost 8 decades after the complete elucidation of the pathway, new
insights continue to emerge, and reconsideration of the original dogma
of the pathway has even been proposed [15].
Technologies to monitor glucose metabolism with increasing efﬁciencies continue to emerge, taking more and more holistic approaches to map the inter- and intra-cellular interactions. Omics

approaches (metabolomics, proteomics, lipidomics, transcriptomics,
genomics, etc.), employing high-throughput technologies, have
opened up new opportunities in systems-biology, such that different
genotypic/phenotypic levels of intracellular metabolic activities can be
captured in a snapshot with high-precision and efﬁciency [16]. The
massive amount of data generated requires intensive statistical analysis to resolve the underlying processes and, additionally, this data can
be computationally-modelled and simulated to enrich the experimental
observations, guide experimental strategies, and predict pathway kinetics to hypothesise the behaviour of the system and its components
[17,18]. Knowledge and understanding of cellular metabolic dynamics
are essential for differentiation between healthy and diseased cells
[19], identifying target pathways and drug discovery for disease
therapy [12,20e22], etc., which opens up scope for development of
novel strategies for dynamic, non-destructive, single-cell metabolic
analysis. Dynamic analysis of the systemic interactions remain a
challenge, given the multi-omics analysis techniques are destructive to
cell/tissue samples, and demand multiple experimental setups.
Furthermore, omics technologies are restricted by the minimum
sample detection limit which makes single-cell analysis complicated,
as due to the cellular heterogeneity some features might be missed in
analysis of cell populations [23]. Cellomics, also referred to as highcontent analysis/screening, involves labelling, imaging, analysis, and
visualisation of the biological system to provide a better alternative for
decoding single-cell dynamics. However, labelling techniques are, by
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deﬁnition, limited to visualisation of what has been labelled and assume an a priori knowledge of the process to be monitored. As an
alternative, vibrational spectroscopy provides a label-free, holistic
representation of the biomolecular content of the sample, in real-time
[24]. It is a relatively well established analytical approach, compared to
modern omics approaches, but is being increasingly investigated for
clinical and pharmaceutical applications, given the development of
ever more sophisticated microscopic instrumentation enabling cellular
and subcellular analysis, as well as tools to datamine and analyse the
complex datasets [25e27]. Although many approaches to date have
focussed on analysis of tissues, and bioﬂuids for disease diagnostics
[28,29], the potential of vibrational spectroscopy for cellular and
subcellular analysis of dynamic processes is increasingly being
explored [30e34], including for in vitro drug screening and toxicology
analyses of cell lines [27,35e37].
In this paper, we review the medical relevance of the glycolytic
pathway in detail and brieﬂy explore the current state of art for its
monitoring and modelling. The future perspectives speciﬁcally focuses
on the potential of vibrational microspectroscopic techniques, which
are non-destructive, and can be harnessed to gain insights into the
cellular metabolism in a label-free, dynamic manner. Additionally, the
high resolution of microspectroscopy can be used for analysis at
organelle level in a single-cell.
2. THE GLYCOLYSIS PATHWAY: CURRENT UNDERSTANDING
Glycolysis is a ten-step anaerobic process (Figure 1_A) divided into two
phases. The ﬁrst ﬁve steps are collectively referred to as the preparatory/investment phase, in which the six-carbon glucose molecule is
broken down into two, three-carbon carbon molecules by investing
energy, while the proceeding ﬁve steps are termed the payoff phase, in
which energy is produced.
The ﬁrst, irreversible, regulatory investment step in glycolysis is
phosphorylation of glucose to glucose-6-phosphate (G6P), catalysed
by hexokinase (cofactors Mgþþ, Mnþþ). Consuming one adenosine
triphosphate (ATP) molecule ensures maximum intake of glucose as
the added charge prevents it diffusing out of the cell [38]. Glucokinase
is a differentially regulated isozyme of hexokinase, present only in the
liver and beta cells along with hexokinase [39]. Glucokinase is stimulated by insulin and supressed by cyclic adenosine monophosphate in
the liver, and activated by increased glucose concentration in the
pancreas [40,41]. Glucokinase has signiﬁcantly lower afﬁnity to
glucose, lowering its uptake in liver cells during starvation to spare
glucose for more important organs. Glucokinase remains unaffected by
the accumulation of G6P and continues to phosphorylate glucose
(Figure 1_B.2). Hence, the presence of an extra isozyme helps liver
cells regulate the glucose concentration in the body.
The second irreversible, regulatory investment step is the phosphorylation of fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate
(F1,6BP), catalysed by phosphofructokinase (PFK, cofactor Mgþþ),
consuming one ATP molecule. It is the commitment step of glycolysis,
as, if the reaction proceeds beyond this point, it must proceed through
the entire pathway. Deactivation of PFK leads to F6P accumulation
which is freely converted back to G6P, as per Le Chatelier’s principle
[42], and inhibits hexokinase (Figure 1_B.1). The two types of PFK; PFK
1 and PFK 2 in humans have the same substrate but yield F1,6BP and
F2,6BP, respectively. PFK2 has additional phosphatase activity along
with the kinase activity. The PFK enzyme is allosterically inhibited by
ATP, citrate and upregulated by AMP and F2,6BP (Figure 1_C). The
feed forward stimulation in liver promotes the activity of PFK using
F2,6 P.
2

The ﬁrst energy production step (step 6 in the pathway, payoff phase)
is the conversion of glyceraldehyde 3-phosphate (G3P) to 1,3bisphosphoglycerate (1,3BPG), which is catalysed by glyceraldehyde3-phosphate dehydrogenase (GAPDH), an oxidoreductase enzyme.
This reaction converts a Nicotinamide adenine dinucleotide (NAD)
molecule to NADH, which can be further utilised in electron transport
chain to produce ATP. Further, 1,3BPG is converted to 3phosphoglycerate (step 7 in pathway) which produces an ATP molecule from adenosine diphosphate (ADP). This reaction is catalysed by
phosphoglycerate kinase (cofactors Mgþþ, Mnþþ).
The ﬁnal step of glycolysis, conversion of phosphoenol pyruvate to
pyruvate (step 10 in the pathway) is catalysed by the pyruvate kinase
(PK) (cofactors Mgþþ, Kþþ) enzyme. This is an irreversible regulatory reaction. Elevated levels of ATP and alanine create negative
feedback to inhibit PK. Fructose 1,6 bisphosphate stimulates this
enzyme in the absence of ATP. In liver cells, an additional L isozyme of
PK is present along with the M isozyme (L-liver, M-muscle) but the L
form is predominant. The L form is controlled by phosphorylation,
which deactivates the molecule (Figure 1_D). During starvation, this
enzyme isoform phosphorylates to avoid taking in glucose.
The net energy produced by glycolysis is two ATP molecules (four
produced, two consumed) and two reduced NAD molecules. In addition
to glucose catabolism and energy production, glycolysis produces
several relevant molecules essential for cell sustenance. G6P can enter
the pentose phosphate pathway, producing several pentose sugars
and NADPH for cholesterol and fatty acid synthesis. G6P is a starting
point for glycogen synthesis. G3P produces glycerol, essential for
production of triglycerides and phospholipids. Glycolysis is directly and
indirectly involved in the biosynthesis of several amino acids, which are
the building blocks of proteins.
In the quiescent state, the glycolytic rate is at the basal level (Pasteur’s
effect) [43] and the majority of the ATP produced is by mitochondrial
oxidative phosphorylation pathway (OxPP). However, during cell proliferation, the OxPP rate drops, and high glycolytic rate is observed.
This leads to drop in NAD/NADH ratio which is compensated by converting pyruvate to lactate, oxidising NADH to NAD (Figure 1_A) [43].
3. MEDICAL RELEVANCE AND THERAPIES
Glucose is generally considered the main carbon source, and the
glycolytic pathway signiﬁcantly impacts cellular metabolism and proliferation [44]. Glycolysis dysfunction plays a key role in diabetes and
obesity [10], cancer [45], neurodegenerative diseases such as
amyotrophic lateral sclerosis, Alzheimer’s and Parkinson’s disease
[46,47].
Diabetes is caused by the improper functioning of the glycolysis, due
to compromised cellular signalling. Insulin secretion is regulated by
glycolysis [10], and hepatic glucose production (HGP) was shown to be
an effective way to maintain euglycemia [48e50]. Type-1 diabetes
insulin insufﬁciency leads to a decrease in glycolysis rate, whereas
type-2 diabetes hyperinsulinemia leads to an increased rate of
glycolysis in liver, pancreatic beta cells and adipose tissue [10].
Hexokinase-2 (HK2) inﬂuenced by insulin [51,52] plays an essential
role in diabetes [52,53] and was reduced speciﬁcally (28  0.5% and
31  4% diabetic, 40  0.5% and 47  7% control at 0.11 and
11.0 mM/L of glucose, respectively [54]) in the skeletal muscles of
type-2 diabetic patients [54,55]. Under hyperinsulinemic conditions
(450 pmol m2. min1 for 3 h [55]; 40 and 240 mU.m2. min1 [56]),
upregulation of HK2 activity in muscles and adipose tissues was
observed in obese and normal patients (93  20 control 1, 194  37
control 2, 127  35 obese [55] and 5  0.08 control, 4.33  0.66
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obese (averages of soluble/particulate and both hyperinsulinemic ﬂow
rates) [56]), but was reduced in type-2 diabetic patients (9  18 [55];
3.10  0.10 [56]). Genetic mutation, leading to loss of function of
glucokinase [57e59], decreased glucose phosphorylation and
decreased insulin secretion [60], was observed in ‘maturity onset
diabetes of young’ patients. Glucokinase activity was reduced in obese
type-2 patients by about 50% [61] which were later reported to exhibit
active glucokinase mutation leading to hypoglycaemia [62,63]. An
independent risk factor for the development of type-2 diabetes can be
the elevated levels of lactate in plasma (27% aetiologic fraction) [64].
The pyruvate and lactate interconversion rates (diabetic 46  9 to
108  31 and control 21  3 to 50  13 mmol/min/kg) were observed
to be signiﬁcantly elevated, probably due to impaired glucose oxidative
pathway in type-2 diabetes [65]. A single gene or protein cannot
explain the complete pathophysiology of diabetes, hence insights into
the dynamics of glucose catabolism rate could provide an extra layer of
detail for categorising the disease features which may aid in its
therapy [39].
Glucose is the only source of energy to the brain, which performs
differential aerobic respiration to satisfy its rapid energy demands,
undertaking intermittent biosynthesis of metabolites and maintain the
redox states [66]. Aerobic glycolysis fulﬁls the energy requirement of
the membrane bound ATP dependent processes, such as the pumping
action of NAþ/K þ ATPase [67,68]. This process is not restricted to

brain and was observed in human red blood cell membranes [69],
skeletal muscle [70], vascular smooth muscle [71], and neurons [72].
One primary reason for opting such an inefﬁcient process generating
only two over thirty ATP molecules is the rate of production. The higher
rate of glycolysis over OxPP accommodates the small, rapidly changing
energy requirements by the cell/organ [73]. Brain glucosehypometabolism [74], glucose-accumulation [75] and reduced glycolytic pathway ﬂux [75] was observed in Alzheimer’s disease (AD) patients [47,76] and the well documented link between AD and diabetes
can also be plausibly explained by brain hyperglycemia [47], higher
levels of the apolipoprotein E gene (ApoE2) making the brain more
resistant to AD due to increased glycolytic robustness [47]. Glycolytic
dysfunction in peripheral cells was also observed in other neurodegenerative diseases (Huntington’s disease, Parkinson’s disease and
amyotrophic lateral sclerosis) indicating that the pathology of the
disease is not limited to nervous cells and strengthening the notion of
glycolytic dysfunction as a common pathway leading to neurodegeneration [9,47]. A dynamic sense of glycolytic rate to differentiate
the normal from the abnormal could beneﬁt in disease prevention, antiageing strategies and to unravel the mystery of the most essential
organ, the brain!
Mature erythrocytes lack nuclei and mitochondria, making glycolysis
the sole pathway for ATP production [77]. Although rare, the most
common glycolytic abnormality in erythrocytes is PK deﬁciency [78]

Figure 1: Schematic representation of Glycolysis pathway and the regulatory enzymes. (A) 10 steps of glycolytic pathway. Brown and green arrows represent the preparatory
phase and payoff phase respectively. Yellow curved arrows represent the energy consumption and production nodes. The enzymes involved in each node are written in red and the
regulatory enzymes are highlighted with green background. The energy production during quiescence and proliferation from cytoplasm (glycolysis) and mitochondria (blue ovals
with TCA cycle) are represented with yellow stars. Circles emerging from different nodes of the pathway represent the precursor molecules which end up in different pathways.
(B.1) The inhibition of PFK leads to accumulation of F6P which goes into homeostasis with G6P. The excessive accumulation of G6P leads to inhibition of hexokinase. (B.2) The
isozyme of hexokinase, glucokinase with low afﬁnity to glucose is represented with a thin arrow. Both the enzymes phosphorylate glucose to G6P. The effect of PFK inhibition on
respective enzyme is indicated in purple. The regulation of the enzymes in beta cells and liver is represented by the regulatory molecule and its effect is represented by an arrow.
(C) Two PFK enzymes in the glycolytic pathway are represented and the effect of the regulatory molecules is indicated in purple. The different rates of activity of both the enzymes
is represented by the thicknesses of the arrows. (D) Final regulatory steps of the pathway with two isoforms of the pyruvate kinase are represented. The phosphorylation of L
isoform leads to deactivation of the enzyme and the effect of the regulatory molecules is represented in purple.
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resulting in lack of energy, abnormal membrane function, potassium
and water leakage from the cell, increase of calcium concentration
and ultimately to cell rigidity, loss of ﬂexibility, early susceptibility to
splenic sequestration which collectively leads to haemolysis [78].
Other enzyme abnormalities linked to hexokinase, phosphoglycerate
kinase, phosphoglucose isomerase, phosphofructokinase, aldolase,
triosephosphate isomerase, etc., have also been identiﬁed but are
scarce [79].
The role of glycolysis is signiﬁcant in cancer research, as tumour cells
perform glycolysis at a rate which is wten times higher than normal
cells. A comprehensive understanding of glycolysis can foster cancer
detection, identiﬁcation, classiﬁcation, and cure by identifying drug
targets. In the 1920s, Warburg observed that tumour cells consume
surprisingly large amounts of glucose, compared to normal cells [43].
Multiple mechanisms leading to this phenomenon such as mitochondrial DNA mutation, nuclear DNA mutation, oncogenic transformation and the inﬂuence of the microenvironment around a tumour
are reported [80e82]. The phenomenon is being exploited using ﬂuorodeoxyglucose positron emission tomography (FDG-PET) for the
detection of tumours [83]. Studies on proliferating lymphocyte cells
demonstrated that around 90% of the pyruvate was being converted to
lactate, concluding that the Warburg effect is not speciﬁc to tumour
cells [84e87]. Increased activity of hexokinase (79% breast cancer
patients [88]), lactate dehydrogenase A (in 61.8% mixed stage gastric
carcinoma patients with 56.3% survival rate compared to 78.4%
survival rate in low activity patients [89]) and glyceraldehyde-3phosphate (2.5 fold under hypoxia for 24 h in MFC-7 cells [90]) in
tumours and cancer cell-lines was reported [88e90]. Inhibiting cancer
cell proliferation, apoptosis induction and reversing multidrug resistance can be achieved by silencing the overexpressed enzymes such
as lactate dehydrogenase A and PK [91e93]. However, these enzymes
are multifunctional. For instance, hexokinase and enolase are critical in
transcription regulation [94,95] and glucose-6-phosphate isomerase
might affect cell motility [96]. Hence, identiﬁcation of novel tumour
features and drug targets which are distinct from normal cells is crucial
for the disease therapy. The glycolysis pathway dynamics can be used
for classiﬁcation and drug discovery for different cancer phenotypes.
The Warburg effect and subsequent rewiring of cellular metabolism
was also observed during atherosclerosis [97], whereby vulnerable
human atherosclerotic lesions exhibit an enhanced expression of
glycolytic markers compared to stable plaques [98]. The main risk
factors for atherosclerosis include vascular endothelial cell (VEC) injury,
lipid deposition, inﬂammatory and immune dysfunction, the former
being considered one of the main triggers driving the occurrence and
development of subclinical atherosclerosis [99,100]. Several seminal
studies have provided compelling evidence that VECs are highly
glycolytic, in both healthy and dysfunctional activated states [101].
VECs in healthy vessels are quiescent and actively maintain blood ﬂow,
vascular tone, and transport across the vessel wall. However, in
response to extracellular events, VECs can become activated and
induce angiogenic or pro-inﬂammatory signals [101]. Activation is
accompanied by changes in cellular metabolism that provide energy
and metabolic intermediates that fuel important biological processes
including angiogenesis, inﬂammation and barrier function [102]. VECs
can become adhesive and adopt a prothrombotic phenotype that orchestrates a vascular inﬂammatory response, including leukocyte
recruitment and increased vascular permeability [99]. In these pathological conditions, the glycolytic process is compromised, leading to
metabolic processes being activated to compensate for ATP shortage
and to increased oxidative stress, cell dysfunction, as well as cell death
[103,104]. Upon activation, VEC metabolism becomes disordered,
4

represented by increased glycolysis and expression level and activity of
fatty acid synthase [103]. These enhance the proliferation, migration,
and inﬂammation of VECs, leading to VEC dysfunction and vascular
disease.
Similar studies of the metabolism of vascular smooth muscle cells
(vSMCs) have revealed an important role for glycolysis in atherosclerosis [105]. During the development of an atherosclerotic plaque,
the accumulation of SMC-like cells following de-differentiation of
medial vSMCs and/or partial myogenic differentiation of resident
vascular stem cell progenitors is accompanied by enhanced aerobic
glycolysis [106]. Thus, modulating VEC and vSMC metabolism via
antiglycolytic therapies may be a potential therapeutic target for
atherosclerosis.
4. GLYCOLYSIS MONITORING TECHNIQUES
For an excellent general review of methodologies employed in monitoring metabolic processes, in vitro and in vivo, the reader is referred to
the work of Duraj et al. [107]. Techniques to monitor the glycolysis
process either as a static snapshot or dynamic process, can be categorised as either top-down or bottom-up approaches [108]. The
bottom-up approach tries to understand individual components or a
smaller network of the system, whereas the top-down approach holistically targets the entire system using high-throughput techniques to
obtain a large dataset [108]. Both approaches rely on advanced
computational methods to model the behaviour of the system, which
will be discussed in section_5. For a mode extensive and detailed
discussion of the techniques, the reader is directed to excellent reviews of statistical/physiochemical modelling [109] and modelling from
top-down and bottom-up approaches [108].
In what is considered a bottom-up approach, monitoring the extracellular acidiﬁcation rate (ECAR) in live cells using simple biochemical
assays, in a kinetic spectrophotometric mode can be used to decode
the dynamics of glycolysis pathway [110]. The ECAR assay can be
coupled to the O2 consumption assay in the same experiment to
quantitatively derive and subtract the CO2 acidiﬁcation as the detection
elements in both assays ﬂuoresce at different wavelengths [111]. This
assay is non-destructive and provides a dynamic proﬁle of glucose
metabolism which can be used for statistical and physiochemical
modelling [112,113]. (Figure 2) represents the data obtained from one
of such dynamic experiments obtained from Agilent Seahorse instrument [114]. The glycolysis rate is at basal level when no glucose is
added, while the cell relies on oxidative phosphorylation for ATP demand [114]. Upon addition of glucose, the cell reduces its oxygen
consumption and the glycolytic rate increases. If the mitochondrial ATP
production is blocked (oligomycin) the cell relies solely on glycolysis for
ATP demand and the glycolysis rate increases to its full capacity [114].
The glycolytic rate drops to basal level if a competitive inhibitor, 2deoxyglucose is added. Mitochondrial respiration also contributes to
the extracellular acidiﬁcation to some extent, which is represented in
(Figure 2_C) [114].
Alternatively, targeting speciﬁc enzymes/metabolites in the pathway
provide more speciﬁc details of the pathway intermediates [115].
Radioactive ((2-deoxy-d-[1,2e3H]-glucose); (2-deoxy-d-[1e14C]glucose); (2-deoxy-2-(18F)-ﬂuoro-D-glucose)) or ﬂuorescent (2-[N-(7nitrobenz-2-oxa-1,3-diaxol-4-yl)amino]-2-deoxyglucose); glucose analogues can provide a reliable quantitative estimate of glucose entering
the glycolytic pathway in a cell [115]. Alternately, the activity of rate
limiting glycolytic enzymes can be determined by quantifying their
catalytic products in vivo [115]. The simplicity and the fact that these
assays can be coupled with several activators/inhibitors make them
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Figure 2: Representative ﬁgure for the dynamic monitoring the OCR and ECAR in C2C12 myoblast cells using Agilent Seahorse instrument. The OCR (A) and ECAR (B) were
monitored dynamically using Agilent Seahorse instrument in C2C12 cells in the basal condition (without any glucose) and the sequential addition of 10 mM glucose, 2 mg/ml
oligomycin (ATP synthase inhibitor/glycolysis stimulator) and 10 mM 2DG (competitive inhibitor of hexokinase and phosphoglucoisomerase). (C) Respiratory (blank column) and
glycolytic (blue column) proton production rate (PPR) form the ‘A’ and ‘B’ experiment. Coloured wedges indicate glycolysis in basal condition (blue) and glycolytic capacity (green)
with their difference as glycolytic reserve. The data is an average of 6 replicates. Reproduced with permission from [114].

extremely useful in pharmaceutical research and development [111].
The data from these assays is suitable for physiochemical and to some
extent statistical modelling [116]. Unfortunately, the cell must be lysed
to quantify/harvest the metabolites/enzymes at ﬁxed time-points to
obtain in situ pathway dynamics. Furthermore, the biochemical assays
are not sensitive enough for single-cell analysis.
Positron emission tomography (PET) uses radiolabelled tracers for
static and dynamic imaging but its use has been largely limited to drug
development and clinical research [117]. Sequential and simultaneous
PET and magnetic resonance imaging (MRI) have emerged in recent
years as kinetic imaging strategies with high clinical importance [117].
In this technique, a positron-emitting isotopic compound is noninvasively injected intravenously in trace quantities and its biodistribution is used to infer the physiological and biochemical processes such as glycolysis [117]. The potential beneﬁt of kinetic
analysis has been demonstrated for a number of tracers such as 18-Flabelled 2-deoxy-2-D-glucose (18F-FDG; tumour detection, response
monitoring, tumour detection estimates) [118e120], 18F-DOPA
(tumour-grade differentiation) [121], 18F-FMISO (tumour hypoxia
response to therapy) [122], 18F-FLT (brain tumour progression, glioma
therapy response modelling) [123,124]. This technique can potentially
be used for in situ kinetic analysis in humans for diagnostics using
statistical and physiochemical modelling with a downside of requiring
radiolabels.

Green ﬂuorescent proteins (GFP) are often used to study protein
localisation, dynamics and interactions in single living cells [125,126].
They can be tagged to virtually any protein to form a ﬂuorophore
[125,127], and advancement in GFP biology has aided in optimised
expression for a wide range of cell types [128], several variants of
which have already been developed to tag and monitor different proteins simultaneously [129,130]. Microscopic techniques such as
ﬂuorescence recovery after photobleaching (FRAP), ﬂuorescence
resonance energy transfer (FRET) and ﬂuorescence correlation spectroscopy (FCS) have also evolved in laser scanning microscopy [128]
and dynamic imaging can be performed to obtain large kinetic data
sets for statistical as well as physiochemical modelling. A representation of confocal microscopy and FRAP dynamic imaging with pon and
histone2B proteins, tagged with GFP and RFP, respectively, in mitotically dividing drosophila sensory organ precursor cell is shown in
(Figure 3) [131]. Although it can be monitored dynamically, the technique is limited by the fact that it only visualises what has been
labelled, which assumes an a priori knowledge of the process to be
monitored, and/or multiple probes for a more systemic understanding.
More systemic approaches, which can be considered top-down,
employ different omics techniques, including genomics [132,133],
transcriptomics [134e136], proteomics [137,138] and metabolomics
[139], by which the entire genome, transcriptome, proteome, and
metabolome of the system can be analysed as a snapshot of the
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Figure 3: Fluorescence microscopy of GFP-Pon protein (green) and Histone2B-RFP protein (red) in live drosophila sensory organ precursor cell to monitor the localisation of pon
protein during mitotic cell division. Yellow arrowheads indicate cortical blebbing, blue arrowheads indicate random accumulations of GFP-Pon, and the white arrowhead indicates
early GFP-Pon crescent; NEBD stands for nuclear-envelope breakdown. Reproduced with permission from [131].

quenched system using high-throughput techniques [140e142].
These techniques are usually used in a targeted manner, focusing on
speciﬁc aspects of a systemic response, such that they can also be
considered bottom-up approaches [143e145].
Next generation sequencing has emerged as a powerful tool in scientiﬁc research and diagnostics, making use of fragmented nucleotide
sequences to cost effectively construct a sequencing library of millions
of nucleotide strands simultaneously in a short span of time with high
accuracy [146,147]. The small sequenced fragments are then aligned
using complex computer simulations to obtain complete or targeted
genome/transcriptome sequences [146,147]. Genomic data can be
used to accurately draw the pathway map (physiochemical modelling)
for the whole cell while the quantitative transcriptomic data can be
used for statistical modelling [148]. Predicting the phenotype from
genotype is complex and the correlation is not yet clear. Schwannhäusser et al. established that the mRNA expression level was the best
predictor of protein levels and could explain 40% of protein level
variability in mouse ﬁbroblast cells, while protein stability had a minor
role [149]. However, this may not be universally the case, as another
study in embryonic stem cells reported that changes in protein levels
are not accompanied by changes in corresponding mRNA expression
level [150]. Schwannhäusser et al. further indicated that, under
different conditions, rate constants may vary and the protein stability
might have a bigger role at single cell level or as a result of any
perturbation [149] as protein degradation is involved in regulation of
many cellular processes [151]. Although, the cellular genome does not
change much during the lifetime of the organism, the cellular transcriptome is highly dynamic and depends on the state of the system.
Several approaches for a wider range of systems at single and multicellular levels are already developed for dynamic transcriptome analysis [152e155], but by the nature of the analytical technology, these
approaches are destructive and rely on quenching the systemic information at pre-ﬁxed states.
Single-cell genomics rely on the numerous approaches [156e158] for
genome ampliﬁcation so there is enough for sequencing, to get insights into the genome evolution, e.g. in cases such as cancer, and to
understand the genomic basis of a speciﬁc phenotype, which is missed
in bulk sequencing of a population [159,160]. Similarly, single-cell
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transcriptomics requires addition of an extra step of converting the
transcripts into cDNA using reverse transcriptase which can be
ampliﬁed and sequenced [160]. Alternatively, RNA hybridisation
probes attached with ﬂuorescent compounds can be used for speciﬁc
sequence identiﬁcation and use of different RNA probes can aid in
building comprehensive transcriptome [161,162]. Single-cell transcriptomics is preferred over single-cell proteomics due to the ease of
ampliﬁcation over the difﬁculties associated with protein ampliﬁcation
and ﬁnds applications in studying gene dynamics, RNA splicing and
cell typing [160].
The cellular proteome/metabolome deﬁnes the cellular phenotype. The
proteomics and metabolomics approaches employ high-throughput
analytical tools such as mass spectrometry (MS) or nuclear magnetic resonance spectroscopy (NMR) [163]. Quantitative detection of
molecules/metabolites aid in statistical/physiochemical modelling and
to determine the relative activity of the pathway. The proteomic data
can be complicated for pathway ﬂux analysis, due to the different
layers of enzymatic regulation (post-translational modiﬁcations, allosteric control, etc.) and the lack of in vivo kinetic parameters for many
enzymes [164]. Modern metabolomics approaches utilise stable isotopic tracers of hydrogen, carbon, nitrogen, oxygen, and sulphur
incorporated in the primary carbon source. As pathways have unique
carbon transitions, analysing the location of the stable isotope in the
amino acids produced can reveal the chosen pathway. Despite these
developments, there remain physical limitations, as only a small
subset of metabolites can be quantiﬁed [165,166]. These limitations
can be metabolite related (low abundance, low stability), instrumental
(identical retention in chromatography and MS) [166] and experimental
metabolism quenching, as high metabolome turnover rates are on the
sub-second timescales [167] and the quenching methods induce
leakage in cells [168e170]. Metabolic ﬂux analysis describes the true
ﬂux through the pathway at a given state, but to get a dynamic view of
the system which would describe the systems transition through
different states at a molecular level would require a wide array of
experimentation [171] which would again encounter the above
mentioned challenges. Visualising the dynamics of the single-cell
metabolome and proteome is possible using time-lapse microscopy
or using time-resolved omics experiments [172e174].
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For single-cell proteomics, several strategies are applied which entail
either tagging the proteins of interest with a speciﬁc antibody attached
to a distinctive ﬂuorophore [175,176], quantum dot [177], etc., or
tagging the genome with a ﬂuorescent protein, to be analysed using
ﬂuorescence microscopy [178,179]. Alternatively, the proteins can be
tagged with rare metal isotopes for mass cytometry [180,181]. Major
steps for single cell proteomics by MS (SCoPE-MS) based analysis are
sample preparation, separation and detection. To deal with the protein
ampliﬁcation issue, several groups focus on oocytes or very early
cleavage cell stage, due to their large size and abundance of proteins
[182e184] while some working on mammalian cells (10e15 mm
diameter) combine carrier-cells and single-cell barcoding [185,186].
The second generation of SCoPE-MS [187], SCoPE2 [188,189] further
increase throughput of sample preparation over 100 fold by miniaturising sample preparation step such as MAMS (Micro-Arrays for MS)
which achieves high speed aliquoting by exploiting differences in
wettability among recipient sites and surrounding areas [190]. Sample
preparation can involve several steps to purify the proteins to some
extent and then further separate them via different chromatographic
techniques, before detection by MS/MSeMS. Although transcriptomics
and proteomics have the same purpose, transcriptomics does not
consider post-translational regulation.
Several ﬂuorescence microscopy-based strategies can be used for
single-cell metabolomics studies, such as usage of ﬂuorescent proteins which illuminate when bound to the metabolite [191]. Not
requiring ﬂuorescent proteins for metabolites of interest and the
detection sensitivity in the femtomole range, MS has been most
frequently used for single-cell metabolomics [192]. Single-cell
metabolomics using mass spectroscopy is progressing rapidly as the
challenges are accepted and creatively explored by an increasing
community and the continuous effort are moving the ﬁeld towards
more sensitive techniques with higher throughput, quantitative abilities
and decreased technical variability [193,194]. The future development
is directed towards techniques with high-throughput, high-sensitivity
for molecules with low abundance/low ionisation efﬁciency, good
replicability for single-cell metabolite detection [193]. The metabolomics proﬁle illustrates how the cell adapts to environmental
stresses at a molecular level, providing a dynamic understanding of the
cell [191].
Given the complex nature of cells and the interactions within the
different levels of central dogma (geno-pheno-envirotype interactions), combinatorial/multi-omics/pan-omics have emerged
which can extend the scope of harvested information to elucidate the
interactions between biological entities for precision medicine and
biomarker discovery [195,196]. Proteogenomics harness the advantages of both genotype and phenotype by identifying/quantifying
translated nucleotide sequences to generate candidate proteins to
discover single amino acid variants (SAAV), splice proteoforms and
additionally genome re-annotation to discover novel coding sequences which have found signiﬁcant applications in precision
medicine [197,198]. Epigenetics, on the other hand, deals with
changes in the biochemistry, not by modiﬁcations in the genomic
sequence, but by methylation, acetylation, phosphorylation, ubiquitylation, sumolyation, chromatin modiﬁcations, etc., which are
responsible for several illnesses, behaviours, and other health indicators [199]. A wide array of multi-omics platforms are now
available as databases and data processing toolboxes [200].
Although these sophisticated systemic strategies have come a long
way, further development is required to establish in situ, nondestructive, label free approaches which can aid in dynamic subcellular analysis.

5. IN SILICO MODELLING
I. silico modelling approaches describe a system in terms of simple
mathematical equations to mimic the behaviour of the system [201] as
described by the top down and bottom up approaches described in
section_4 [108].
Modelling from the bottom up requires detailed datasets covering the
full dynamic range of each reaction to deﬁne the behaviour of the
system [108]. Homeostatic control in vivo does not allow the gathering
of such detailed datasets, and hence the bottom-up approach relies on
in vitro with cell and cell-free experiments to ﬁt the parameters [108].
Often, models based on in vitro cell-free enzyme kinetics analysis draw
from repositories of kinetic data to fulﬁl the data requirement [108], but
trying to understand the in vivo metabolism dynamics in terms of
in vitro cell-free kinetics of the constituent enzymes can generate
erroneous results due to the discrepancy between the in vitro cell free
rates and in vivo ﬂuxes [202].
The semi-quantitative indices analysis using dynamic PET and MRI
imaging can be used for kinetic modelling [117]. Dynamic imaging of
GFP generates large, kinetically complex data sets which can be
analysed with computational models to quantify biophysical properties
of molecules and even processes [203]. This approach of computational cell biology can be used to kinetically monitor the essential
pathways, mechanisms and controls of biological processes in realtime [203].
The systems biology approach of ‘metabolic ﬂux analysis’ (MFA), also
known as ‘ﬂuxomics’, is a physiological counterpart of different omics
techniques. MFA is an end result of the multiomics interplay which
holistically describes the operation of the entire system by inferring the
complex model from the available in vivo data [108]. Largely based on
13
C tracers [164], MFA has developed over the last three decades from
a black box balance approach of a few reactions [204] to simultaneous
measurement of hundreds of metabolic ﬂuxes [205], including
reversible and parallel reactions [206]. Flux balance analysis (FBA),
13
C-ﬂuxomics and 13C constraint based FBA are different approaches
of MFA and can be used in measuring dynamic, stationary and semistationary metabolite ﬂuxes [164]. In principle, given the mathematical
complexity of kinetic models, these are more challenging to construct
and rely on approximate kinetic formalisms for parameter ﬁtting [207e
209]. This approach uses simpliﬁed equations which often result in
loss of kinetic details, thermodynamic consistency and prevent identiﬁcation of novel regulatory mechanisms [108].
The emergence of open source resources such as Cell Designer [210],
which enable biochemical pathway models to be simply drawn, but
also kinetically modelled by the user, have made the approaches much
more accessible. Model/Graphical representation by Systems Biology
Markup Language (SBML) [211] and Systems Biology Graphical Notation (SBGN) [212] means that the user deﬁned models can be
interfaced with many other databases, for pathway enrichment [213], a
technique becoming increasingly popular in predictive toxicology
[214]. Once validated with experimental data under different conditions, the models can accurately predict cellular metabolism at
different steady states [215,216]. Numerous tools for steady state
kinetic modelling are freely available [217e222].
Modelling approaches can be differentiated as statistical and physiochemical modelling. Statistical modelling is employed when difﬁcult
to manage, abundant data is available, but the insight into the structure
of system is sparse i.e., components of the system, their interaction
and regulation. As no assumption can be made about the underlying
mechanism of the system due to the lack of structure, the objective of
modelling is to identify relevant variables or dimensions in the system
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[109]. This type of modelling employs statistical tools to connect
different layer of data and gap ﬁlling. These models, however, rely on
the predictability of the dimension considered to be signiﬁcant e.g. a
principal component analysis. Genome scale modelling falls under this
method. Several statistical tools such as KEGG mapper, Metaboanalyst, etc. Are freely available for statistical modelling
[217,222,223]. Berndt et al. modelled murine liver cancer cells using
shotgun proteomics approach by LC-MS/MS [224]. They found signiﬁcant upregulation of PFK (L isoform) and GAPDH enzymes. A twofold
increase of the isoforms A and C of fructose-bisphosphate aldolase
which preferentially contribute to glycolytic rate unlike the isoform B
which contributes to gluconeogenic rate were observed [224]. Kelly
et al. developed a kinetic model of hepatic glycolysis to observe the
effect of the extracellular environment on the cytosolic free NAD/NADH
in a cell culture [225]. From the data obtained from the model, they
concluded that cytosolic the NAD/NADH ratio is maintained by two key
enzymes GADPH and lactate dehydrogenase (LDH) [225].
Physicochemical models can be viewed as the translation of a
pathway map into a mathematical form. These models predict speciﬁc biomolecular transformations such as covalent modiﬁcations,
intermolecular associations and localisation as mathematical equations based on a prior knowledge of pathways for which components
and connectivity are well established [226e230]. The equations
describe the identiﬁable processes such as catalysis and assembly
with physical interpretations of parameters such as concentration,
binding afﬁnity and reaction rate [231]. Modelling begins with
identifying the elements in the model and generation of a schematic
describing the interactions between them. These interactions are
further translated into equations which require certain assumptions
to be made for visualising the dynamics of the equations. Although
the models assume how the interactions take place, they also aid in
rapid hypothesis testing and model validation [109]. Ordinary and
partial differential equation can be used for both deterministic and
stochastic modelling. ODEs are most common for deriving simple
mechanistic or empirical equations. Mass action kinetics, rate law
(Michaelis Menten models, Hill kinetics), power law, lin-log approximations and thermokinetic considerations can be used to represent
the effect of involved variables [109]. Maier et al. described a dynamic model for HepG2 cells by quantifying 25 extra and intracellular metabolites by 13C labelling and intermittent metabolite
quantiﬁcation from parallel cultures using high performance liquid
chromatography (HPLC), liquid chromatography-mass spectroscopymass spectroscopy (LC-MS-MS) and gas chromatographyemass
spectroscopy (GCeMS) [232]. The negative control of GAPDH and
positive control of OxPP over glycolytic ﬂux [232] supported the hypothesis of GAPDH and Warburg effect as potential targets for tumour
treatment [232]. Yarmush et al. modelled steatotic HepG2 cells
during defatting for applications in fatty liver transplant [233] by
measuring 28 extracellular metabolites and intracellular triglycerides
using HPLC and commercially available assay kits [233]. They
observed that the glycolytic ﬂux was high while the extracellular
glucose consumption was very small compared to glycogenolysis,
indicating that glycolysis and fatty acid co-oxidation might co-exist in
steatotic HepG2 cells [233].
6. FUTURE PERSPECTIVES: LABEL FREE MICROSPECTROSCOPIC
ANALYSIS
Vibrational spectroscopic microscopy has emerged as a label-free
alternative to currently employed techniques, which can provide molecular speciﬁc signatures of biological processes and function at a
8

cellular and subcellular level. The spectrum comprises contributions
from each molecular bond and is a “signature” or “ﬁngerprint” which
is characteristic of a material, or changes associated with a physical or
chemical process. In complex samples, notably biological cells or
tissue, the spectroscopic signature incorporates characteristics of all
constituent functional groups of lipids, proteins, nucleic acids and other
speciﬁc biomolecules and metabolites [24,234] (Figure 4 [235]).
Infrared (IR) absorption and Raman scattering are the most common
forms of vibrational spectroscopy, and both provide a molecule
ﬁngerprint, although through different fundamental physical principles.
IR absorption is the result of electric dipole transition between vibrational states, whereas Raman spectroscopy is based on an inelastic
scattering process caused by the polarisability change of a molecule
[24]. The OH group has a particular strong IR absorption, whereas it is
a relatively weak Raman scatterer, and therefore the latter is often
promoted for in vivo applications, or live cell imaging [28]. Raman is
often conducted at visible or near IR wavelengths, and therefore, in
microscopic mode, can have spatial resolution of <1 mm, whereas the
longer wavelengths of the IR (5e20 mm) limit its spatial resolution.
Additionally, certain molecules such as amino acid residues, SeS
disulphide bridges, CeS linkages from proteins and nucleic acids
are better highlighted in Raman spectroscopy compared to IR spectroscopy [24].
Using Raman and/or IR microspectroscopy, quantitative spectroscopic
changes attributable to the biochemical processes occurring during
cell culture and mitosis [236,237], proliferation [238], differentiation
and activation [239e241], adhesion [242], death [243] and invasion
[244] have previously been documented. Confocal Raman microspectroscopy has been demonstrated to provide detail at a subcellular
level, of ﬁxed or live cells, in 2D and/or 3D culture environments [245e
247], as shown for the example of a Raman microspectroscopic map
of an A549 human lung cancer cell, analysed by K-means clustering
(Figure 4_I), which differentiates the nucleolar (yellow) regions of the
nucleus (purple), which is in turn differentiated from regions of the
cytoplasm (blue), according to their characteristic mean spectra
(Figure 4_II) [248]. The analysis also unambiguously identiﬁed the
presence of polystyrene nanoparticles (green) in the cytoplasm of the
cell, identiﬁed by its characteristic spectrum (Figure 4_III). Similar
studies have demonstrated the detection of cellular mitochondrial
distribution [249] and phagosomes [250]. Label free analysis can
identify signatures of subcellular phenomena not evident in a labelled
approach, as for example the mechanistic role of accumulation of the
chemotherapeutic agent doxorubicin in the nucleolus of cells [251],
and potentially guide the identiﬁcation of new biomarkers of cellular
events. Thepphilpou et al. have reviewed the applications of different
modes of vibrational spectroscopy for cellular analysis [252], and the
reader is also referred to the graphical summary of the different
methodologies in the work of Paraskevaidi et al. [253].
Critically, however, the analysis and interpretation of the spectral responses remains a challenge, even in the hands of “specialists”. By
their very nature, label free techniques register all species within the
sampling area, and identiﬁcation of speciﬁc responses requires
multivariate analytical techniques to data-mine the differential signatures, which are characteristic of cell injury events or response
pathways. The characteristic spectral response can have (additive)
contributions of increased or decreased concentrations of any or all
constituent biomolecules, but also more complex contributions due to
conformational, environmental (pH etc.) changes, and it is apparent
that a novel combinatorial approach based on identiﬁcation of the
(differential) spectroscopic signatures rather than speciﬁc bands
associated with speciﬁc biomolecules, may be more appropriate. The
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Figure 4: : I) (A) Microscopic image of an A549 lung cancer cell, showing the reduced area identiﬁed for spectral mapping. (B) K-Means cluster map of the Raman proﬁle of the
same reduced area. II) K-means spectra of clusters 3 (Adrepresenting nucleoli), 6 (Bdrepresenting nucleus), 1 and 4 (C and D, both from the cytoplasm). Spectra are offset for
clarity. III) K-means spectrum of Cluster 5 (A), compared to the Raman spectrum polystyrene nanoparticles (B). Spectra are offset for clarity. (Reproduced with permission from
[248]).

spectroscopic signature is, in itself, characteristic of the key cellular
event, and can be used to identify and quantify it, in a “spectralomics”
approach [36]. The evolution of the characteristic signatures may
therefore be used to characterise the cellular pathway. The reported
reproducibility of subcellular signatures of drug uptake, mechanisms of
action and cellular response [36,251,254e257], as well as nanoparticle trafﬁcking and toxicity [37,258e261], in multiple cell lines
suggests that such an approach to label free characterisation of
cellular processes according to characteristic spectroscopic signatures
is feasible. Munck introduced similar terminology of the “spectral
phenome”, in the discussion of the near IR spectroscopic analysis of a
barley endosperm mutant model, evaluated by chemometrics [204],
although metabolic pathways were not explicitly explored.
Although it cannot be considered truly label free, several studies have
demonstrated that stable isotope labelling can be utilised in Raman
spectroscopy for in situ monitoring of a kinetic process. Xu et al. used
deuterated glucose and deuterated naphthalene as sole carbon
sources for Escherichia coli and Pseudomonas sp. Cultures, respectively, and demonstrated that the Carbon-Deuterium vibration at
w2700 cm1 could be used to semi quantitatively and sensitively
monitor the metabolism of the carbon sources, although the kinetics of
the process were not explicitly monitored spectroscopically [262].
Zhang et al. used a similar technique based on simulated Raman
scattering (SRS), which images the metabolic dynamics of newly
synthesised macromolecules in a cell according to the signatures of CD bonds derived from a deuterated glucose precursor [263]. They
described the utility of this technique to visualise temporally separated
glucose populations by using spectral differences of glucose isotopologues [263]. With a detection limit of 10 mM of C-D bonds, this

technique is effective for tracing functional utilisation of glucose
derived anabolic products over the conventional glucose imaging
techniques which are limited to monitoring glucose uptake or catabolism activity [263]. Noothalpati and Shigeto explored ergosterol
biosynthesis as a model system in single living ﬁssion yeast cells using
stable isotope labelled Raman microspectroscopy to establish the
technique for in vivo metabolic analysis [264]. Their study revealed the
intrinsic spectra and relative abundances of all isotopomers of
ergosterol, partially or fully substituted with 13C, when the spatially
resolved Raman spectra was analysed by multivariate spectral data
analysis [264]. Li et al. showed the application of stable isotope
labelling and single cell Raman spectroscopy to link the food chain
from 13C-glucose carbon substrate to E. coli microbe up to Caenorhabditis elegans predator in a quantitative and non-destructive
manner [265]. Similarly, spatiotemporal and functional relationships
between proteins and lipid droplets was dynamically visualised by 13C
incorporation and in vivo time-lapse Raman imaging to illustrate the
potential in proteome visualisation at intervals of 1 h over time periods
of up to 40 h, without ﬂuorophore tagging in single ﬁssion yeast cells
[266]. Weber et al. explored the utility of Raman microspectroscopy
coupled with stable isotope probing for monitoring the growth rates of
heterologous bacteria at single-cell resolution, based on the 13C- and
12
C-isotopologues of the amino acid phenylalanine [267], identiﬁable
by the strong phenylalanine ring breathing modes 966 and
1,002 cm1). Using a robust curve ﬁtting process for precise deconvolution of partially overlapping peaks, the identiﬁed peaks provided an
accurate reporter probe for quantiﬁcation of cellular isotope fractional
abundances (fcell) for complex 13C-labelled carbon source assimilation
in E. coli in time-course experiments. The fcell and bacterial growth
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rates were validated using isotope ratio mass-spectroscopy and optical
density measurements respectively.
Analysis of the evolution of spectral proﬁles in cells has not been
common, although kinetic, mechanistic approaches to analysis of organisms and organs have become well accepted in pharmaco kinetics/
dynamics [268] and systems biology [269,270]. Mukherjee et al. used
Raman mirospectroscopy to monitor effects of culture conditions in
bacterial growth, although the spectral analysis was large based on
peak ratios [271]. Mair et al. demonstrated that oscillatory kinetics of
many glycolytic intermediates of yeast can be analysed by time
resolved FT-IR spectroscopy [272]. Consecutive FT-IR-spectra of
Saccharomyces carlsbergensis yeast extract were taken over a period
of 1e2 h. The yeast spectra at all time points were least squares ﬁtted
with linear combinations of spectra of standard solutions of glycolytic
intermediates (G6P, F6P, F1, 6P2, PEP, Pyr) and related compounds
(ATP, ADP, AMP, NADH, NAD, trehalose, glycogen, ethanol, glycerol,
phosphate), such that the kinetics of glycolytic intermediates could be
extracted from the reconstructed spectra (Figure 5).
Poonprasartporn and Chan conducted an FTIR spectroscopic study of
live HEP2G cells, grown in either normal glucose (3.8 mM) or high
glucose (25 mM) medium and compared their spectroscopic proﬁles
after incubation times of 24, 48 and 72 h [273]. In the normal glucose
treated cells, increases in the absorbance of bands associated with
nucleic acid PO2 phosphate stretching and symmetric stretching of
COO, from fatty acids, amino acids and carboxylate metabolites. In
contrast, the high glucose treated cells exhibited a clear reduction of
the PO2 stretching mode band after 24 h, and further spectral
changes in the region w1000e1200 cm1 after 48 and 72 h, linked
to the glycogen and ATP:ADP ratio. The study supports the use of the
technique for monitoring metabolic processes in cells, and a more
recent study from the same authors compared the effect of two antidiabetic drugs on insulin resistant HEPG2 cells [274]. The analysis
mainly focused on the glycogen peaks at 1150, 1080 and 1020 cm1,
which served as spectroscopic markers of cellular response to insulin.
They discovered that the spectral changes were highly speciﬁc to the
drug applied and were able to differentiate between the spectral

proﬁles of normal and insulin resistant cells, the lack of response to
insulin and the restoration of insulin resistance upon drug treatment in
the resistant cells.
Pleitez et al. demonstrated the potential of mid-infrared optoacoustic
microscopy (MiROM) for label-free, bond-selective, live-cell metabolic
imaging for spatiotemporal dynamic monitoring of lipids, proteins and
carbohydrates [275]. MiROM, based on mid-IR vibrational excitation
and positive-contrast detection, offers greater sensitivity in the
ﬁngerprint spectral regions as compared to modern vibrational spectroscopic approaches which measure a reduction of transmission or
reﬂected light intensity [276e279], as evident from the lower limit of
detection (LOD) (2.5 mM for DMSO and 1.5 mM for albumin) using laser
powers in hundreds of microwatts (330 mW for DMSO and 500 mW for
albumin), thereby signiﬁcantly lowering the risk of phototoxicity to the
cells [280]. They demonstrated MiROM could efﬁciently differentiate
lipids (2,853 cm1), proteins (sum of amide I (1,700 and 1,600 cm1)
and II (1,550 cm1)), and carbohydrates (sum of 1,081 and
1,084 cm1) to generate MiROM micrographs [275]. They further
explored its potential for dynamic cellular analysis and used the
optoacoustic contrasts to generate box plots to quantify the phenome
at ﬁxed time points to observe its dynamics [275]. Further, lipid and
protein dynamics during isoproterenol (ISO) induced lipolysis in white
and brown adipocytes was also showcased [275]. Lipid (2,857 cm1)
and protein (1,550 cm1) were recorded every 5 min before and after
addition of isoproterenol [275]. The lipid content slowly increased
indicating lipogenesis until the lipogenesis was induced which induced
nearly linear decrease in lipid content [275]. The study is signiﬁcant for
single-cell analysis, as differential lipolysis rates were observed in both
white and brown adipocytes while some cells even remained unaffected [275].
Accurately data mining the characteristic signatures of the subcellular
interactions and processes represents a challenge. Multivariate curve
resolution-alternating least squares (MCR-ALS) has been proposed as
a more ﬂexible approach to study the evolution of cellular processes
[281]. MCR-ALS models the temporal evolution of the spectral dataset
by considering a set of components whose concentrations evolve at

Figure 5: Extraction of the kinetics of glycolytic intermediates with low concentration from the reconstructed spectra (Reproduced with permission from [272]).
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different rates and have characteristic spectral features. MCR-ALS
iteratively ﬁts the target spectrum by least squares ﬁtting multiple
components, either provided a priori, based on previous or external
information of the system, or estimated using techniques such as
Singular Value Decomposition (SVD) [282]. Then, an initial estimation
of concentration matrix or spectra is made by using information about
the chemical components involved or using other methods such as
Evolving Factor Analysis (EFA) [283]. Perez-Guaita et al. have previously demonstrated the application of MCR-ALS to gain insight into the
pharmacodynamics and biochemical changes associated with drug
exposure in an in vitro cellular model, as measured using Raman
microspectroscopy [284], and a multimodal combination of Raman and
Infrared microspectroscopies [285]. MCR-ALS uses external information and constraints to guide the iterative process, which can include
initial estimates of the spectra of the starting point and intermediate
constituents of the pathway, which can each be constrained to ensure
that they contribute non negatively, and collectively constrained to
ensure “closure”, or mass balance, in the hope of reducing the ambiguity of the result and leading to chemically interpretable solutions.
One such constraint involves the introduction of kinetic equations to ﬁt
the evolution of the components to known chemical relations within the
system, in a so-called hard-soft modelling approach. The approach
has previously been used to model the evolution of spectra of very
simple reactions (e.g., A- > B) [286], but more recently Perez-Guaita
et al. have demonstrated that it is possible to constrain the least
squares ﬁtting procedure by a set of ordinary differential equations
[30]. The approach was validated using the example of cellular uptake

and binding of the chemotherapeutic drug doxorubicin, in vitro cell,
accurately reproducing the spectroscopic proﬁles and uptake rates in
simulated models (Figure 6).
The hard-soft MCR-ALS approach opens up the possibility of data
mining the label free Raman microspectroscopic responses of a
cellular metabolic process described by a phenomenological rate
equation, or systems biology approach. Such a framework of label free,
subcellular Raman microspectroscopic analysis, combined with a kinetic, mechanistic modelling approach, to underpin chemometric
analysis protocols, provides a basis for the unambiguous interpretation
of the evolution of the characteristic spectroscopic signatures. Note
however, that these spectroscopic signatures, for example of the
interaction of an intercalating agent in the nucleus of a cell, may be
constituted by contributions of chemical moieties from multiple
different biomolecules, or changes to them, and is a characteristic
signature of the cellular event or process, rather than of any speciﬁc
biomarker(s). The approach potentially lays the foundation for a
spectralomics paradigm of label free high content spectroscopic
analysis of cellular function, providing a holistic view of the cellular
processes to augment conventional labelled and omics approaches.
The combinatorial approach could guide identiﬁcation of key biomarker
targets for more in depth labelled and omics approaches, and, in its
own right, could ﬁnd future applications in preclinical drug screening
and toxicology among others. However, it should be noted that the
exploration of the techniques for such complex evolution of biochemically complex systems is very much in its infancy. The continuous evolution of novel and hybrid label free spectroscopic approaches

Figure 6: (A) Kinetic evolution of simulated drug uptake and binding (dark blue), and cellular response (green), (B) Raman spectrum of the drug, doxorubicin (dark blue), simulated
spectral signature of drug binding (cyan) and of the subsequent cellular response (green), (C) predicted kinetic evolution of the MCR-ALS components, (D) MCR-ALS components,
extracted after 50 iterations, (E) evolution of the kinetic constraint constants over 200 iterations of the MCR-ALS algorithm, (F) initial and ﬁnal (after 200 iterations) constants
employed in the MCR-ALS model. (Reproduced with permission from [30]).
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promises increased capacity to rapidly screen cellular and subcellular
processes in real time. Coherent Raman spectroscopic techniques
promise large area screening at up to video rates [279,287], while the
development of quantum cascade laser sources which are tunable
across the mid IR region of the spectrum have given rise to hybrid
techniques such as atomic force microscopy detected IR spectroscopy
(AFM-IR) [288,289], as well as photoacoustic [290], and photothermal
techniques, the most recent incarnations of which enable simultaneous measurement of IR and Raman on the same spot [291].
Nevertheless, it is crucial to demonstrate that techniques such as
MCR-ALS and other multivariate datamining technique can reliably
extract the signatures of interest, and that they can be interpreted in
terms of their biochemical origin.
AUTHOR CONTRIBUTIONS
Nitin Patil: Conceptualization, Writing - Original Draft, Orla Howe:
Writing - Original Draft, Paul Cahill: Writing - Original Draft. Hugh J.
Byrne: Conceptualization, Writing - Original Draft, Supervision, Funding acquisition.
DATA AVAILABILITY
No data was used for the research described in the article.
FUNDING ACKNOWLEDGEMENT
NP is funded by Science Foundation Ireland (SFI) Frontiers for the Future Award 20/
FFPP/8517

CONFLICT OF INTEREST
None declared.

REFERENCES
[1] Deberardinis RJ, Thompson CB. Cellular metabolism and disease: what do
metabolic outliers teach us? Cell 2012;148:1132e44. http://dx.doi.org/
10.1016/j.cell.2012.02.032.
[2] Chandel NS. Glycolysis. Cold Spring Harbor Perspect Biol 2021;13:a040535.
http://dx.doi.org/10.1101/CSHPERSPECT.A040535.
[3] Romano AH, Conway T. Evolution of carbohydrate metabolic pathways. Res
Microbiol 1996;147:448e55. http://dx.doi.org/10.1016/0923-2508(96)
83998-2.
[4] Harris RA. Glycolysis overview. Encycl Biol Chem Second; 2013. p. 443e7.
http://dx.doi.org/10.1016/B978-0-12-378630-2.00044-X.
[5] Barnett JA. A history of research on yeasts 5: the fermentation pathway.
Yeast 2003;20:509e43. http://dx.doi.org/10.1002/YEA.986.
[6] Bugrim A, Nikolskaya T, Nikolsky Y. Early prediction of drug metabolism and
toxicity: systems biology approach and modeling. Drug Discov Today 2004;9:
127e35. http://dx.doi.org/10.1016/S1359-6446(03)02971-4.
[7] Kell DB. Systems biology, metabolic modelling and metabolomics in drug
discovery and development. Drug Discov Today 2006;11:1085e92. http://
dx.doi.org/10.1016/j.drudis.2006.10.004.
[8] Yu L, Chen X, Sun X, Wang L, Chen S. The glycolytic switch in tumors: how
many players are involved? J Cancer 2017;8:3430e40. http://dx.doi.org/
10.7150/jca.21125.
[9] Bell SM, Burgess T, Lee J, Blackburn DJ, Allen SP, Mortiboys H. Peripheral
glycolysis in neurodegenerative diseases. Int J Mol Sci 2020;21:1e19. http://
dx.doi.org/10.3390/IJMS21238924.

12

[10] Guo X, Li H, Xu H, Woo S, Dong H, Lu F, et al. Glycolysis in the control of
blood glucose homeostasis. Acta Pharm Sin B 2012;2:358e67. http://
dx.doi.org/10.1016/J.APSB.2012.06.002.
[11] Ussher JR, Elmariah S, Gerszten RE, Dyck JRB. The emerging role of
metabolomics in the diagnosis and prognosis of cardiovascular disease. J Am
Coll Cardiol 2016;68:2850e70. http://dx.doi.org/10.1016/J.JACC.2016.09.
972.
[12] Ganapathy-Kanniappan S, Geschwind JFH. Tumor glycolysis as a target for
cancer therapy: progress and prospects. Mol Cancer 2013;12:1e11. http://
dx.doi.org/10.1186/1476-4598-12-152.
[13] Abboud G, Choi SC, Kanda N, Zeumer-Spataro L, Roopenian DC, Morel L.
Inhibition of glycolysis reduces disease severity in an autoimmune model of
rheumatoid arthritis. Front Immunol 2018;9:1973. http://dx.doi.org/10.3389/
ﬁmmu.2018.01973.
[14] Wang Z, Wang N, Chen J, Shen J. Emerging glycolysis targeting and drug
discovery from Chinese medicine in cancer therapy. Evid Based Complement Alternat Med 2012;2012:13. http://dx.doi.org/10.1155/2012/
873175.
[15] Schurr A, Gozal E. Glycolysis at 75: is it time to tweak the ﬁrst elucidated
metabolic pathway in history? Front Neurosci 2015;9:170. http://dx.doi.org/
10.3389/FNINS.2015.00170/BIBTEX.
[16] Chuang HY, Hofree M, Ideker T. A decade of systems biology. Annu Rev Cell
Dev Biol 2010;26:721e44. http://dx.doi.org/10.1146/annurev-cellbio100109-104122.
[17] Braun R. Systems analysis of highethroughput data. Adv Exp Med Biol
2014;844:153. http://dx.doi.org/10.1007/978-1-4939-2095-2_8.
[18] Machado D, Costa RS, Rocha M, Ferreira EC, Tidor B, Rocha I. Modeling
formalisms in systems biology. Amb Express 2011;1:1e14. http://dx.doi.org/
10.1186/2191-0855-1-45/TABLES/2.
[19] Liberti MV, Locasale JW. The warburg effect: how does it beneﬁt cancer
cells? Trends Biochem Sci 2016;41:211. http://dx.doi.org/10.1016/
J.TIBS.2015.12.001.
[20] Jezewski AJ, Lin Y-H, Reisz JA, Culp-Hill R, Barekatain Y, Yan VC, et al.
Targeting host glycolysis as a strategy for antimalarial development. bioRxiv
2021. http://dx.doi.org/10.1101/2020.10.09.331728.
[21] Sanzey M, Abdul Rahim SA, Oudin A, Dirkse A, Kaoma T, Vallar L, et al.
Comprehensive analysis of glycolytic enzymes as therapeutic targets in the
treatment of glioblastoma. PLoS One 2015;10:e0123544. http://dx.doi.org/
10.1371/JOURNAL.PONE.0123544.
[22] Verlinde CLMJ, Hannaert V, Blonski C, Willson M, Périé JJ, FothergillGilmore LA, et al. Glycolysis as a target for the design of new antitrypanosome drugs. Drug Resist Updates 2001;4:50e65. http://dx.doi.org/
10.1054/DRUP.2000.0177.
[23] Altschuler SJ, Wu LF. Cellular heterogeneity: do differences make a difference? Cell 2010;141:559e63. http://dx.doi.org/10.1016/J.CELL.2010.
04.033.
[24] Byrne HJ, Sockalingum GD, Stone N. Raman microscopy: complement or
competitor? In: Moss D, editor. RSC anal. Spectrosc. Ser. Royal Society of
Chemistry; 2011. p. 105e43. http://dx.doi.org/10.1039/978184973199700105.
[25] Byrne HJ, Ostrowska KM, Nawaz H, Dorney J, Meade AD, Bonnier F, et al.
Vibrational spectroscopy: disease diagnostics and beyond. Challenges Adv.
Comput. Chem. Phys. 2014;14:355e99. http://dx.doi.org/10.1007/978-94007-7832-0_13.
[26] Old OJ, Fullwood LM, Scott R, Lloyd GR, Almond LM, Shepherd NA, et al.
Vibrational spectroscopy for cancer diagnostics. Anal Methods 2014;6:
3901e17. http://dx.doi.org/10.1039/C3AY42235F.
[27] Jamieson LE, Byrne HJ. Vibrational spectroscopy as a tool for studying drugcell interaction: could high throughput vibrational spectroscopic screening
improve drug development? Vib Spectrosc 2017;91:16e30. http://dx.doi.org/
10.1016/J.VIBSPEC.2016.09.003.

MOLECULAR METABOLISM 66 (2022) 101635 Ó 2022 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

[28] Baker MJ, Byrne HJ, Chalmers J, Gardner P, Goodacre R, Henderson A, et al.
Clinical applications of infrared and Raman spectroscopy: state of play and
future challenges. Analyst 2018;143:1735e57. http://dx.doi.org/10.1039/
c7an01871a.
[29] Paraskevaidi M, Matthew BJ, Holly BJ, Hugh BJ, Thulya CPV, Loren C, et al.
Clinical applications of infrared and Raman spectroscopy in the ﬁelds of
cancer and infectious diseases. Appl Spectrosc Rev 2021;56:804e68. http://
dx.doi.org/10.1080/05704928.2021.1946076.
[30] Pérez-Guaita D, Quintás G, Farhane Z, Tauler R, Byrne HJ. Combining pharmacokinetics and vibrational spectroscopy: MCR-ALS hard-and-soft modelling
of drug uptake in vitro using tailored kinetic constraints. Cells 2022 2022;11:
1555. http://dx.doi.org/10.3390/CELLS11091555. 11, Page 1555.
[31] Liu Z, Parida S, Prasad R, Pandey R, Sharma D, Barman I. Vibrational
spectroscopy for decoding cancer microbiota interactions: current evidence
and future perspective. Semin Cancer Biol 2021. http://dx.doi.org/10.1016/
J.SEMCANCER.2021.07.004.
[32] Richards O, Jenkins C, Grifﬁths H, Paczkowska E, Dunstan PR, Jones S, et al.
Vibrational spectroscopy: a valuable screening and diagnostic tool for obstetric disorders? Front Glob Women’s Heal 2021;1:610582. http://dx.doi.org/
10.3389/fgwh.2020.610582.
[33] Pence I, Mahadevan-Jansen A. Clinical instrumentation and applications of
Raman spectroscopy. Chem Soc Rev 2016;45:1958e79. http://dx.doi.org/
10.1039/c5cs00581g.
[34] Byrne HJ, Bonnier F, Casey A, Maher M, McIntyre J, Efeoglu E, et al.
Advancing Raman microspectroscopy for cellular and subcellular analysis:
towards in vitro high-content spectralomic analysis. Appl Opt 2018;57:E11.
http://dx.doi.org/10.1364/ao.57.000e11.
[35] Tomellini SA, Finn JW. Vibrational spectroscopy in drug discovery, development and production. Encycl Anal Chem; 2000. http://dx.doi.org/10.1002/
9780470027318.A1923.
[36] Farhane Z, Nawaz H, Bonnier F, Byrne HJ. In vitro label-free screening of
chemotherapeutic drugs using Raman microspectroscopy: towards a new
paradigm of spectralomics. J Biophot 2018;11. http://dx.doi.org/10.1002/
jbio.201700258.
[37] Efeoglu E, Maher MA, Casey A, Byrne HJ. Label-free, high content screening
using Raman microspectroscopy: the toxicological response of different cell
lines to amine-modiﬁed polystyrene nanoparticles (PS-NH2). Analyst
2017;142:3500e13. http://dx.doi.org/10.1039/c7an00461c.
[38] Rajas F, Gautier-Stein A, Mithieux G. Glucose-6 phosphate, a central hub for
liver carbohydrate metabolism. Metabolites 2019;9. http://dx.doi.org/
10.3390/METABO9120282.
[39] Bouché C, Serdy S, Kahn CR, Goldﬁne AB. The cellular fate of glucose and its
relevance in type 2 diabetes. Endocr Rev 2004;25:807e30. http://dx.doi.org/
10.1210/ER.2003-0026.
[40] Magnuson MA. Glucokinase gene structure. Functional implications of molecular genetic studies. Diabetes 1990;39:523e7. http://dx.doi.org/10.2337/
diab.39.5.523.
[41] Bedoya FJ, Matschinsky FM, Shimizu T, O’Neil JJ, Appel MC. Differential
regulation of glucokinase activity in pancreatic islets and liver of the rat. J Biol
Chem
1986;261:10760e4.
http://dx.doi.org/10.1016/s0021-9258(18)
67451-4.
[42] Peters B. Chemical equilibrium. React. Rate theory rare events simulations.
2017. p. 19e37. http://dx.doi.org/10.1016/b978-0-44-456349-1.00002-7.
[43] DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of
cancer: metabolic reprogramming fuels cell growth and proliferation.
Cell Metabol 2008;7:11e20. http://dx.doi.org/10.1016/J.CMET.2007.10.
002.
[44] Teuwen LA, Geldhof V, Carmeliet P. How glucose, glutamine and fatty acid
metabolism shape blood and lymph vessel development. Dev Biol 2019;447:
90e102. http://dx.doi.org/10.1016/j.ydbio.2017.12.001.

[45] Alfarouk KO, Verduzco D, Rauch C, Muddathir AK, Bashir AHH, Elhassan GO,
et al. Glycolysis, tumor metabolism, cancer growth and dissemination. A new
pH-based etiopathogenic perspective and therapeutic approach to an old
cancer question. Oncoscience 2014;1:777e802. http://dx.doi.org/10.18632/
oncoscience.109.
[46] Bell SM, Burgess T, Lee J, Blackburn DJ, Allen SP, Mortiboys H. Peripheral
glycolysis in neurodegenerative diseases. Int J Mol Sci 2020;21:1e19. http://
dx.doi.org/10.3390/ijms21238924.
[47] Zhang X, Alshakhshir N, Zhao L. Glycolytic metabolism, brain resilience, and
Alzheimer’s disease. Front Neurosci 2021;15:476. http://dx.doi.org/10.3389/
FNINS.2021.662242/BIBTEX.
[48] Morral N. Novel targets and therapeutic strategies for type 2 diabetes. Trends
Endocrinol Metabol 2003;14:169e75. http://dx.doi.org/10.1016/S10432760(03)00031-6.
[49] Kurukulasuriya R, Link J, Madar D, Pei Z, Richards S, Rohde J, et al. Potential
drug targets and progress towards pharmacologic inhibition of hepatic
glucose production. Curr Med Chem 2012;10:123e53. http://dx.doi.org/
10.2174/0929867033368556.
[50] Saltiel AR. New perspectives into the molecular pathogenesis and treatment
of type 2 diabetes. Cell 2001;104:517e29. http://dx.doi.org/10.1016/S00928674(01)00239-2.
[51] Vogt C, Ardehali H, Iozzo P, Yki-Jarvinen H, Koval J, Maezono K, et al.
Regulation of hexokinase II expression in human skeletal muscle in vivo.
Metabolism 2000;49:814e8. http://dx.doi.org/10.1053/meta.2000.6245.
[52] Printz RL, Koch S, Potter LR, O’Doherty RM, Tiesinga JJ, Moritz S, et al.
Hexokinase II mRNA and gene structure, regulation by insulin, and evolution.
J Biol Chem 1993;268:5209e19. http://dx.doi.org/10.1016/S0021-9258(18)
53521-3.
[53] Chang PY, Jensen J, Printz RL, Granner DK, Ivy JL, Moller DE. Overexpression
of hexokinase II in transgenic mice: evidence that increased phosphorylation
augments muscle glucose uptake. J Biol Chem 1996;271:14834e9. http://
dx.doi.org/10.1074/jbc.271.25.14834.
[54] Vestergaard H, Bjørbæk C, Hansen T, Larsen FS, Granner DK, Pedersen O.
Impaired activity and gene expression of hexokinase II in muscle from noninsulin-dependent diabetes mellitus patients. J Clin Invest 1995;96:2639e
45. http://dx.doi.org/10.1172/JCI118329.
[55] Laville M, Bernard C, Lyon U, Vega N, Vidal H. Regulation by insulin of gene
expression in human skeletal muscle and adipose tissue: evidence for
speciﬁc defects in type 2 diabetes. Am Diabetes Assoc 2001. http://
dx.doi.org/10.2337/diabetes.50.5.1134.
[56] Pendergrass M, Koval J, Vogt C, Diabetes HYJ. Insulin-induced hexokinase II
expression is reduced in obesity and NIDDM. 1998 undeﬁned Am Diabetes
Assoc 1998. http://dx.doi.org/10.2337/diabetes.47.3.387.
[57] Hattersley AT, Turner RC, Patel P, O’Rahilly S, Hattersley AT, Patel P, et al.
Linkage of type 2 diabetes to the glucokinase gene. Lancet 1992;339:1307e
10. http://dx.doi.org/10.1016/0140-6736(92)91958-B.
[58] Froguel P, Vaxillaire M, Sun F, Velho G, Zouali H, Butel MO, et al. Erratum:
close linkage of glucokinase locus on chromosome 7p to early-onset noninsulin-dependent diabetes mellitus (Nature (1992) 356 (162-164)). Nature
1992;357:607. http://dx.doi.org/10.1038/357607c0.
[59] Froguel P, Zouali H, Vionnet N, Velho G, Vaxillaire M, Sun F, et al. Familial
hyperglycemia due to mutations in glucokinase – deﬁnition of a subtype of
diabetes mellitus. N Engl J Med 1993;328:697e702. http://dx.doi.org/
10.1056/NEJM199303113281005.
[60] Matschinsky FM. A lesson in metabolic regulation inspired by the glucokinase
glucose sensor paradigm. Diabetes 1996;45:223e41. http://dx.doi.org/
10.2337/diab.45.2.223.
[61] Caro JF, Triester S, Patel VK, Tapscott EB, Frazier NL, Dohm GL. Liver
glucokinase: decreased activity in patients with type II diabetes. Horm Metab
Res 1995;27:19e22. http://dx.doi.org/10.1055/S-2007-979899.

MOLECULAR METABOLISM 66 (2022) 101635 Ó 2022 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

13

Review
[62] Christesen HBT, Jacobsen BB, Odili S, Buettger C, Cuesta-Munoz A,
Hansen T, et al. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes 2002;51:
1240e6. http://dx.doi.org/10.2337/diabetes.51.4.1240.
[63] Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, et al. Familial
hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med
1998;338:226e30. http://dx.doi.org/10.1056/nejm199801223380404.
[64] Ohlson LO, Larsson B, Björntorp P, Eriksson H, Svärdsudd K, Welin L, et al.
Risk factors for Type 2 (non-insulin-dependent) diabetes mellitus. Thirteen
and one-half years of follow-up of the participants in a study of Swedish men
born in 1913. Diabetologia 1988;31:798e805. http://dx.doi.org/10.1007/
BF00277480.
[65] Avogaro A, Toffolo G, Miola M, Valerio A, Tiengo A, Cobelli C, et al. Intracellular lactate- and pyruvate-interconversion rates are increased in muscle
tissue of non-insulin-dependent diabetic individuals. J Clin Invest 1996;98:
108e15. http://dx.doi.org/10.1172/JCI118754.
[66] Vaishnavi SN, Vlassenko AG, Rundle MM, Snyder AZ, Mintun MA, Raichle ME.
Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci U S A
2010;107:17757e62. http://dx.doi.org/10.1073/pnas.1010459107.
[67] Magistretti PJ, Chatton JY. Relationship between L-glutamate-regulated
intracellular Naþ dynamics and ATP hydrolysis in astrocytes. J Neural
Transm 2005;112:77e85. http://dx.doi.org/10.1007/s00702-004-0171-6.
[68] Pellerin L, Magistretti PJ. Excitatory amino acids stimulate aerobic glycolysis
in astrocytes via an activation of the naþ/kþ atpase. Dev Neurosci 1996;18:
336e42. http://dx.doi.org/10.1159/000111426.
[69] Mercer RW, Dunham PB. Membrane-bound ATP fuels the Na/K pump: studies
on membrane-bound glycolytic enzymes on inside-out vesicles from human
red cell membranes. J Gen Physiol 1981;78:547e68. http://dx.doi.org/
10.1085/jgp.78.5.547.
[70] Okamoto KEN, Wang W, Rounds JAN, Chambers EA, Jacobs DO. ATP from
glycolysis is required for normal sodium homeostasis in resting fast-twitch
rodent skeletal muscle. Am J Physiol Endocrinol Metab 2001;281. http://
dx.doi.org/10.1152/AJPENDO.2001.281.3.E479.
[71] Campbell JD, Paul RJ. The nature of fuel provision for the Naþ,K(þ)-ATPase
in porcine vascular smooth muscle. J Physiol 1992;447:67e82. http://
dx.doi.org/10.1113/jphysiol.1992.sp018991.
[72] Wu K, Aoki C, Elste A, Rogalski-Wilk AA, Siekevitz P. The synthesis of ATP by
glycolytic enzymes in the postsynaptic density and the effect of endogenously
generated nitric oxide. Proc Natl Acad Sci U S A 1997;94:13273e8. http://
dx.doi.org/10.1073/pnas.94.24.13273.
[73] Tager HS. Biochemistry: a functional approach. JAMA, J Am Med Assoc
1984;251:1095. http://dx.doi.org/10.1001/jama.1984.03340320071034.
[74] Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative
stress in preclinical Alzheimer’s disease. Ann N Y Acad Sci 2008;1147:180e
95. http://dx.doi.org/10.1196/ANNALS.1427.007.
[75] An Y, Varma VR, Varma S, Casanova R, Dammer E, Pletnikova O, et al.
Evidence for brain glucose dysregulation in Alzheimer’s disease. Alzheimer’s
Dementia 2018;14:318e29. http://dx.doi.org/10.1016/J.JALZ.2017.09.011.
[76] Vlassenko AG, Gordon BA, Goyal MS, Su Y, Blazey TM, Durbin TJ, et al.
Aerobic glycolysis and tau deposition in preclinical Alzheimer’s disease.
Neurobiol Aging 2018;67:95e8. http://dx.doi.org/10.1016/J.NEUROBIOLAGING.2018.03.014.
[77] Van Wijk R, Van Solinge WW. The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis. Blood 2005;106:4034e42. http://
dx.doi.org/10.1182/BLOOD-2005-04-1622.
[78] Climent F, Roset F, Repiso A, de la Ossa P. Red cell glycolytic enzyme
disorders caused by mutations: an update. Cardiovasc Hematol Disord: Drug
Targets 2009;9:95e106. http://dx.doi.org/10.2174/187152909788488636.
[79] Valentine WN, Tanaka KR, Paglia DE. Hemolytic anemias and erythrocyte
enzymopathies. Ann Intern Med 1985;103:245e57. http://dx.doi.org/10.
7326/0003-4819-103-2-245.

14

[80] Heiden MGV, Cantley LC, Thompson CB. Understanding the warburg effect:
the metabolic requirements of cell proliferation. Science 2009;324:1029e33.
http://dx.doi.org/10.1126/SCIENCE.1160809. 80-.
[81] Stubbs M, Grifﬁths JR. The altered metabolism of tumors: HIF-1 and its role
in the Warburg effect. Adv Enzym Regul 2010;50:44e55. http://dx.doi.org/
10.1016/j.advenzreg.2009.10.027.
[82] Bayley JP, Devilee P. The Warburg effect in 2012. Curr Opin Oncol 2012;24:
62e7. http://dx.doi.org/10.1097/cco.0b013e32834deb9e.
[83] Shanmugam M, McBrayer SK, Rosen ST. Targeting the Warburg effect in
hematological malignancies: from PET to therapy. Curr Opin Oncol 2009;21:
531e6. http://dx.doi.org/10.1097/CCO.0b013e32832f57ec.
[84] Wang T, Marquardt C, Foker J. Aerobic glycolysis during lymphocyte proliferation. Natalia 1976;261:702e5. http://dx.doi.org/10.1038/261702a0. 1976
2615562.
[85] Roos D, Loos JA. Changes in the carbohydrate metabolism of mitogenically
stimulated human peripheral lymphocytes: II. Relative importance of
glycolysis and oxidative phosphorylation on phytohaemagglutinin stimulation. Exp Cell Res 1973;77:127e35. http://dx.doi.org/10.1016/00144827(73)90561-2.
[86] Hedeskov CJ. Early effects of phytohaemagglutinin on glucose metabolism of
normal human lymphocytes. Biochem J 1968;110:373e80. http://dx.doi.org/
10.1042/BJ1100373.
[87] Brand K. Glutamine and glucose metabolism during thymocyte proliferation.
Pathways of glutamine and glutamate metabolism. Biochem J 1985;228:
353e61. http://dx.doi.org/10.1042/BJ2280353.
[88] Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL. Expression of
hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol
2002;29:443e53. http://dx.doi.org/10.1016/S0969-8051(02)00288-3.
[89] Kolev Y, Uetake H, Takagi Y, Sugihara K. Lactate dehydrogenase-5 (LDH-5)
expression in human gastric cancer: association with hypoxia-inducible factor
(HIF-1a) pathway, angiogenic factors production and poor prognosis. Ann
Surg Oncol 2008;15:2336e44. http://dx.doi.org/10.1245/S10434-0089955-5.
[90] Higashimura Y, Nakajima Y, Yamaji R, Harada N, Shibasaki F, Nakano Y,
et al. Up-regulation of glyceraldehyde-3-phosphate dehydrogenase gene
expression by HIF-1 activity depending on Sp1 in hypoxic breast cancer
cells. Arch Biochem Biophys 2011;509:1e8. http://dx.doi.org/10.1016/j.
abb.2011.02.011.
[91] Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, et al. Warburg effect in
chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes Taxolresistant cancer cells to Taxol. Mol Cancer 2010;9. http://dx.doi.org/
10.1186/1476-4598-9-33.
[92] Shi H-S, Li D, Zhang J, Wang Y-S, Yang L, Zhang H-L, et al. Silencing of
pkm2 increases the efﬁcacy of docetaxel in human lung cancer xenografts in
mice. Wiley Online Libr 2010;101:1447e53. http://dx.doi.org/10.1111/
j.1349-7006.2010.01562.x.
[93] Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, et al.
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Therapeut 2009;8:626e35.
http://dx.doi.org/10.1158/1535-7163.MCT-08-1049.
[94] Pastorino J, Hoek J. Hexokinase II: the integration of energy metabolism and
control of apoptosis. Curr Med Chem 2005;10:1535e51. http://dx.doi.org/
10.2174/0929867033457269.
[95] Ogino T, Yamadera T, Mizumoto K, Nonaka T, Imajoh-Ohmi S. Enolase, a
cellular glycolytic enzyme, is required for efﬁcient transcription of Sendai
virus genome. Biochem Biophys Res Commun 2001;285:447e55. http://
dx.doi.org/10.1006/bbrc.2001.5160.
[96] Dobashi Y, Watanabe H, Matsubara M, Yanagawa T, Raz A, Shimamiya T,
et al. Autocrine motility factor/glucose-6-phosphate isomerase is a
possible predictor of metastasis in bone and soft tissue tumours. Wiley
Online Libr 2006;208:44e53. http://dx.doi.org/10.1002/path.1878.

MOLECULAR METABOLISM 66 (2022) 101635 Ó 2022 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

[97] Yvan-Charvet L, Ivanov S. Metabolic reprogramming of macrophages in
atherosclerosis: is it all about cholesterol? J Lipid Atheroscler 2020;9:231e
42. http://dx.doi.org/10.12997/JLA.2020.9.2.231.
[98] Poels K, Schnitzler JG, Waissi F, Levels JHM, Stroes ESG, Daemen MJAP,
et al. Inhibition of PFKFB3 hampers the progression of atherosclerosis and
promotes plaque stability. Front Cell Dev Biol 2020;8. http://dx.doi.org/
10.3389/FCELL.2020.581641.
[99] Gimbrone MA, García-Cardeña G. Endothelial cell dysfunction and the
pathobiology of atherosclerosis. Circ Res 2016;118:620e36. http://
dx.doi.org/10.1161/CIRCRESAHA.115.306301.
[100] Rohlenova K, Veys K, Miranda-Santos I, De Bock K, Carmeliet P. Endothelial
cell metabolism in health and disease. Trends Cell Biol 2018;28:224e36.
http://dx.doi.org/10.1016/J.TCB.2017.10.010.
[101] Li X, Sun X, Carmeliet P. Hallmarks of endothelial cell metabolism in health
and disease. Cell Metabol 2019;30:414e33. http://dx.doi.org/10.1016/
J.CMET.2019.08.011.
[102] Draoui N, De Zeeuw P, Carmeliet P. Angiogenesis revisited from a metabolic
perspective: role and therapeutic implications of endothelial cell metabolism.
Open Biol 2017;7. http://dx.doi.org/10.1098/RSOB.170219.
[103] Leung SWS, Shi Y. The glycolytic process in endothelial cells and its implications. Acta Pharmacol Sin 2021 432 2021;43:251e9. http://dx.doi.org/
10.1038/s41401-021-00647-y.
[104] Magnuson DK, Maier RV, Pohlman TH. Protein kinase C: a potential pathway
of endothelial cell activation by endotoxin, tumor necrosis factor, and interleukin-1. Surgery 1989;106:216e23. http://dx.doi.org/10.5555/URI:PII:
0039606089902110.
[105] Shi J, Yang Y, Cheng A, Xu G, He F. Metabolism of vascular smooth muscle
cells in vascular diseases. Am J Physiol Heart Circ Physiol 2020;319:H613e
31. http://dx.doi.org/10.1152/ajpheart.00220.2020.
[106] Chen Z, Liu M, Li L, Chen L. Involvement of the Warburg effect in non-tumor
diseases processes. J Cell Physiol 2018;233:2839e49. http://dx.doi.org/
10.1002/JCP.25998.
[107] Duraj T, Carrión-Navarro J, Seyfried TN, García-Romero N, Ayuso-Sacido A.
Metabolic therapy and bioenergetic analysis: the missing piece of the puzzle.
Mol Metabol 2021;54:101389. http://dx.doi.org/10.1016/J.MOLMET.2021.
101389.
[108] Saa PA, Nielsen LK. Formulation, construction and analysis of kinetic
models of metabolism: a review of modelling frameworks. Biotechnol Adv
2017;35:981e1003. http://dx.doi.org/10.1016/J.BIOTECHADV.2017.09.
005.
[109] Gerdtzen ZP. Modeling metabolic networks for mammalian cell systems:
general considerations, modeling strategies, and available tools. Adv Biochem Eng Biotechnol 2012;127:71e108. http://dx.doi.org/10.1007/10_
2011_120.
[110] Schwalfenberg M, Carey C, Hynes J, Technologies A. Metabolic proﬁling of
cells in 3D cultures using MitoXpress xtra and pH-xtra assays. [n.d.]
[111] Mcgarrigle R, Carey C, Hynes J. Assessing the impact of drug treatment on
cardiomyocyte function [n.d].
[112] Xintaropoulou C, Ward C, Wise A, Marston H, Turnbull A, Langdon SP.
A comparative analysis of inhibitors of the glycolysis pathway in breast and
ovarian cancer cell line models. Oncotarget 2015;6:25677. http://dx.doi.org/
10.18632/ONCOTARGET.4499.
[113] Mookerjee SA, Goncalves RLS, Gerencser AA, Nicholls DG, Brand MD. The
contributions of respiration and glycolysis to extracellular acid production.
Biochim Biophys Acta Bioenerg 2015;1847:171e81. http://dx.doi.org/10.
1016/J.BBABIO.2014.10.005.
[114] Mookerjee SA, Nicholls DG, Brand MD. Determining maximum glycolytic
capacity using extracellular ﬂux measurements. PLoS One 2016;11:
e0152016. http://dx.doi.org/10.1371/JOURNAL.PONE.0152016.
[115] Teslaa T, Teitell MA. Techniques to monitor glycolysis. Methods Enzymol
2014;542:91. http://dx.doi.org/10.1016/B978-0-12-416618-9.00005-4.

[116] Barend Van Dyk J. Mathematical modelling of glycolysis in skeletal muscle
cells. 2020.
[117] Kotasidis FA, Tsoumpas C, Rahmim A. Advanced kinetic modelling strategies:
towards adoption in clinical PET imaging. Clin Transl Imaging 2014;2:219e
37. http://dx.doi.org/10.1007/s40336-014-0069-8.
[118] Kawai N, Nishiyama Y, Miyake K, Tamiya T, Nagao S. Evaluation of tumor
FDG transport and metabolism in primary central nervous system lymphoma
using [ 18F]ﬂuorodeoxyglucose (FDG) positron emission tomography (PET)
kinetic analysis. Ann Nucl Med 2005;19:685e90. http://dx.doi.org/10.1007/
BF02985117.
[119] Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Kawai N, Satoh K, et al.
Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma. Eur J Nucl Med Mol Imag
2007;34:78e86. http://dx.doi.org/10.1007/S00259-006-0153-Z.
[120] Anzai Y, Minoshima S, Wolf GT, Wahl RL. Head and neck cancer: detection of
recurrence with three-dimensional principal components analysis at dynamic
FDG PET. Radiology 1999;212:285e90. http://dx.doi.org/10.1148/
RADIOLOGY.212.1.R99JL02285.
[121] Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang S-C. 18F-FDOPA
kinetics in brain tumors. Soc Nucl Med 2007;48:1651e61. http://dx.doi.org/
10.2967/jnumed.106.039321.
[122] Thorwarth D, Eschmann SM, Paulsen F, Alber M. A kinetic model for dynamic
[18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol 2005;50:
2209e24. http://dx.doi.org/10.1088/0031-9155/50/10/002.
[123] Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC. 18Fﬂuorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imag
2007;34:1003e11. http://dx.doi.org/10.1007/S00259-006-0354-5.
[124] Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N,
et al. Discriminant analysis of 18F-ﬂuorothymidine kinetic parameters to
predict survival in patients with recurrent high-grade glioma. Clin Cancer Res
2011;17:6553e62. http://dx.doi.org/10.1158/1078-0432.CCR-10-3290.
[125] Tsien RY. The green ﬂuorescent protein. Annu Rev Biochem 1998;67:509e
44. http://dx.doi.org/10.1146/ANNUREV.BIOCHEM.67.1.509.
[126] Matz MV, Fradkov AF, Labas YA, Savitsky AP, Zaraisky AG, Markelov ML,
et al. Fluorescent proteins from nonbioluminescent Anthozoa species. Nat
Biotechnol 1999;17:969e73. http://dx.doi.org/10.1038/13657.
[127] Heim R, Prasher DC, Tsien RY. Wavelength mutations and posttranslational
autoxidation of green ﬂuorescent protein. Proc Natl Acad Sci U S A 1994;91:
12501e4. http://dx.doi.org/10.1073/pnas.91.26.12501.
[128] Lippincott-Schwartz J, Snapp E, Kemvorthy A. Studying protein dynamics in
living cells. Nat Rev Mol Cell Biol 2001;2:444e56. http://dx.doi.org/10.1038/
35073068. 2001 26.
[129] Pepperkok R, Squire A, Geley S, Bastiaens PIH. Simultaneous detection of
multiple green ﬂuorescent proteins in live cells by ﬂuorescence lifetime
imaging microscopy. Curr Biol 1999;9:269e74. http://dx.doi.org/10.1016/
S0960-9822(99)80117-1.
[130] Luo WX, Cheng T, Guan BQ, Li SW, Miao J, Zhang J, et al. Variants of green
ﬂuorescent protein GFPxm. Mar Biotechnol 2006;8:560e6. http://dx.doi.org/
10.1007/s10126-006-6006-8.
[131] Mayer B, Emery G, Berdnik D, Wirtz-Peitz F, Knoblich JA. Quantitative
analysis of protein dynamics during asymmetric cell division. Curr Biol
2005;15:1847e54. http://dx.doi.org/10.1016/j.cub.2005.08.067.
[132] Ståhl PL, Lundeberg J. Toward the single-hour high-quality genome. Annu
Rev Biochem 2012;81:359e78. http://dx.doi.org/10.1146/annurev-biochem060410-094158.
[133] Harrison RJ. Understanding genetic variation and function- the applications of
next generation sequencing. Semin Cell Dev Biol 2012;23:230e6. http://
dx.doi.org/10.1016/j.semcdb.2012.01.006.
[134] Van Vliet AHM. Next generation sequencing of microbial transcriptomes:
challenges and opportunities. FEMS Microbiol Lett 2010;302:1e7. http://
dx.doi.org/10.1111/j.1574-6968.2009.01767.x.

MOLECULAR METABOLISM 66 (2022) 101635 Ó 2022 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

15

Review
[135] Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009;10:57e63. http://dx.doi.org/10.1038/
nrg2484.
[136] Slonim DK, Yanai I. Getting started in gene expression microarray analysis.
PLoS Comput Biol 2009;5. http://dx.doi.org/10.1371/journal.pcbi.1000543.
[137] Thelen JJ, Miernyk JA. The proteomic future: where mass spectrometry
should be taking us. Biochem J 2012;444:169e81. http://dx.doi.org/
10.1042/BJ20110363.
[138] Angel TE, Aryal UK, Hengel SM, Baker ES, Kelly RT, Robinson EW, et al. Mass
spectrometry-based proteomics: existing capabilities and future directions.
Chem Soc Rev 2012;41:3912e28. http://dx.doi.org/10.1039/c2cs15331a.
[139] Reaves ML, Rabinowitz JD. Metabolomics in systems microbiology. Curr Opin
Biotechnol 2011;22:17e25. http://dx.doi.org/10.1016/j.copbio.2010.10.001.
[140] Fondi M, Liò P. Multi -omics and metabolic modelling pipelines: challenges
and tools for systems microbiology. Microbiol Res 2015;171:52e64. http://
dx.doi.org/10.1016/J.MICRES.2015.01.003.
[141] Pavel AB, Sonkin D, Reddy A. Integrative modeling of multi-omics data to
identify cancer drivers and infer patient-speciﬁc gene activity. BMC Syst Biol
2016;10:1e14. http://dx.doi.org/10.1186/S12918-016-0260-9/FIGURES/5.
[142] Reuter JA, Spacek DV, Snyder MP. High-throughput sequencing technologies. Mol Cell 2015;58:586e97. http://dx.doi.org/10.1016/J.MOLCEL.2015.
05.004.
[143] Li P, Su M, Chatterjee M, Lämmerhofer M. Targeted analysis of sugar
phosphates from glycolysis pathway by phosphate methylation with liquid
chromatography coupled to tandem mass spectrometry. Anal Chim Acta
2022;1221:340099. http://dx.doi.org/10.1016/J.ACA.2022.340099.
[144] Gao Y, Fillmore TL, Munoz N, Bentley GJ, Johnson CW, Kim J, et al. Highthroughput large-scale targeted proteomics assays for quantifying pathway
proteins in Pseudomonas putida KT2440. Front Bioeng Biotechnol 2020;8:
1383. http://dx.doi.org/10.3389/FBIOE.2020.603488/BIBTEX.
[145] Lichtenstein D, Mentz A, Sprenger H, Schmidt FF, Albaum SP, Kalinowski J,
et al. A targeted transcriptomics approach for the determination of mixture
effects of pesticides. Toxicology 2021:460. http://dx.doi.org/10.1016/
J.TOX.2021.152892.
[146] Thomas Brenn, Alexander J Lazar, McKee’s pathology of the skin, 2 volume
set E-book - J. Eduardo calonje, Steven Billings - Google Books n.d. https://
books.google.ie/books?
hl¼en&lr¼&id¼pMN1DwAAQBAJ&oi¼fnd&pg¼PP1&dq¼McKee%
27sþPathologyþofþtheþSkinþ2020&ots¼OF1IfQ_fSi&sig¼iGTlURgocz00l3HB9GmDkow_8mE&redir_esc¼y#v¼onepage&q¼next
generation sequencing&f¼false.
[147] Next generation sequencing - an overview | ScienceDirect Topics n.d. https://
www.sciencedirect.com/topics/medicine-and-dentistry/next-generationsequencing.
[148] Salzman J, Jiang H, Wong WH. Statistical modeling of RNA-seq data. Stat Sci
2011;26:62e83. http://dx.doi.org/10.1214/10-STS343.
[149] Schwanhüusser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al.
Global quantiﬁcation of mammalian gene expression control. Nature
2011;473:337e42. http://dx.doi.org/10.1038/NATURE10098.
[150] Lu R, Markowetz F, Unwin RD, Leek JT, Airoldi EM, MacArthur BD, et al.
Systems-level dynamic analyses of fate change in murine embryonic stem
cells. Nature 2009;462:358e62. http://dx.doi.org/10.1038/NATURE08575.
[151] Kirkpatrick DS, Denison C, Gygi SP. Weighing in on ubiquitin: the expanding
role of mass spectrometry-based proteomics. Nat Cell Biol 2005;7:750.
http://dx.doi.org/10.1038/NCB0805-750.
[152] Yang Y, Zhou R, Li W, Liu Y, Zhang Y, Ao H, et al. Dynamic transcriptome
analysis reveals potential long non-coding RNAs governing postnatal pineal
development in pig. Front Genet 2019;10:409. http://dx.doi.org/10.3389/
FGENE.2019.00409/BIBTEX.

16

[153] Liu Z, Yu X, Qin A, Zhao Z, Liu Y, Sun S, et al. Research strategies for singlecell transcriptome analysis in plant leaves. Plant J 2022. http://dx.doi.org/
10.1111/TPJ.15927.
[154] Xu GF, Gong CC, Lyu H, Deng HM, Zheng SC. Dynamic transcriptome analysis
of Bombyx mori embryonic development. Insect Sci 2022;29:344e62. http://
dx.doi.org/10.1111/1744-7917.12934.
[155] Hayashizaki Y, Kanamori M. Dynamic transcriptome of mice. Trends Biotechnol 2004;22:161e7. http://dx.doi.org/10.1016/J.TIBTECH.2004.02.003.
[156] Börgstrom E, Paterlini M, Mold JE, Frisen J, Lundeberg J. Comparison of
whole genome ampliﬁcation techniques for human single cell exome
sequencing. PLoS One 2017;12:e0171566. http://dx.doi.org/10.1371/
JOURNAL.PONE.0171566.
[157] Binder V, Bartenhagen C, Okpanyi V, Gombert M, Moehlendick B, Behrens B,
et al. A new workﬂow for whole-genome sequencing of single human cells.
Hum Mutat 2014;35:1260e70. http://dx.doi.org/10.1002/HUMU.22625.
[158] Babayan A, Alawi M, Gormley M, Müller V, Wikman H, McMullin RP, et al.
Comparative study of whole genome ampliﬁcation and next generation
sequencing performance of single cancer cells. Oncotarget 2016;8:56066e
80. http://dx.doi.org/10.18632/ONCOTARGET.10701.
[159] Kalisky T, Quake SR. Single-cell genomics. Nat Methods 2011 84 2011;8:
311e4. http://dx.doi.org/10.1038/nmeth0411-311.
[160] Wang D, Bodovitz S. Single cell analysis: the new frontier in “omics. Trends
Biotechnol 2010;28:281e90. http://dx.doi.org/10.1016/j.tibtech.2010.03.002.
[161] Lubeck E, Coskun AF, Zhiyentayev T, Ahmad M, Cai L. Single-cell in situ RNA
proﬁling by sequential hybridization. Nat Methods 2014 114 2014;11:360e
1. http://dx.doi.org/10.1038/nmeth.2892.
[162] Chen KH, Boettiger AN, Mofﬁtt JR, Wang S, Zhuang X. Spatially resolved,
highly multiplexed RNA proﬁling in single cells. Science 2015:348. http://
dx.doi.org/10.1126/science.aaa6090. 80-.
[163] Amberg A, Riefke B, Schlotterbeck G, Ross A, Senn H, Dieterle F, et al. NMR
and MS methods for metabolomics. Methods Mol Biol 2017;1641:229e58.
http://dx.doi.org/10.1007/978-1-4939-7172-5_13.
[164] Winter G, Krömer JO. Fluxomics - connecting ’omics analysis and phenotypes. Environ Microbiol 2013;15:1901e16. http://dx.doi.org/10.1111/14622920.12064.
[165] Van Dam JC, Eman MR, Frank J, Lange HC, Van Dedem GWK, Heijnen SJ.
Analysis of glycolytic intermediates in Saccharomyces cerevisiae using anion
exchange chromatography and electrospray ionization with tandem mass
spectrometric detection. Anal Chim Acta 2002;460:209e18. http://
dx.doi.org/10.1016/S0003-2670(02)00240-4.
[166] Luo B, Groenke K, Takors R, Wandrey C, Oldiges M. Simultaneous determination of multiple intracellular metabolites in glycolysis, pentose phosphate
pathway and tricarboxylic acid cycle by liquid chromatography-mass spectrometry. J Chromatogr A 2007;1147:153e64. http://dx.doi.org/10.1016/
j.chroma.2007.02.034.
[167] Koning W de, Dam K van. A method for the determination of changes of
glycolytic metabolites in yeast on a subsecond time scale using extraction at
neutral pH. Anal Biochem 1992;204:118e23. http://dx.doi.org/10.1016/
0003-2697(92)90149-2.
[168] Wittmann C, Krömer JO, Kiefer P, Binz T, Heinzle E. Impact of the cold shock
phenomenon on quantiﬁcation of intracellular metabolites in bacteria. Anal
Biochem 2004;327:135e9. http://dx.doi.org/10.1016/j.ab.2004.01.002.
[169] Bolten CJ, Kiefer P, Letisse F, Portais JC, Wittmann C. Sampling for
metabolome analysis of microorganisms. Anal Chem 2007;79:3843e9.
http://dx.doi.org/10.1021/AC0623888.
[170] Dietmair S, Timmins NE, Gray PP, Nielsen LK, Krömer JO. Towards quantitative metabolomics of mammalian cells: development of a metabolite
extraction protocol. Anal Biochem 2010;404:155e64. http://dx.doi.org/
10.1016/j.ab.2010.04.031.

MOLECULAR METABOLISM 66 (2022) 101635 Ó 2022 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

[171] Antoniewicz MR. Dynamic metabolic ﬂux analysis d tools for probing
transient states of metabolic networks. Curr Opin Biotechnol 2013;24:973e
8. http://dx.doi.org/10.1016/J.COPBIO.2013.03.018.
[172] Sah S, Ma X, Botros A, Gaul DA, Yun SR, Park EY, et al. Space- and timeresolved metabolomics of a high-grade serous ovarian cancer mouse
model. Cancers 2022 2022;14:2262. http://dx.doi.org/10.3390/CANCERS14092262. 14, Page 2262.
[173] Fessenden M. Metabolomics: small molecules, single cells. Natalia
2016;540:153e5. http://dx.doi.org/10.1038/540153a. 2016 5407631.
[174] Papagiannakis A, Niebel B, Wit EC, Heinemann M. Autonomous metabolic
oscillations robustly gate the early and late cell cycle. Mol Cell 2017;65:285e
95. http://dx.doi.org/10.1016/J.MOLCEL.2016.11.018.
[175] Giedt RJ, Pathania D, Carlson JCT, McFarland PJ, del Castillo AF, Juric D,
et al. Single-cell barcode analysis provides a rapid readout of cellular
signaling pathways in clinical specimens. Nat Commun 2018;9:1e10. http://
dx.doi.org/10.1038/s41467-018-07002-6. 2018 91.
[176] Lin JR, Izar B, Wang S, Yapp C, Mei S, Shah PM, et al. Highly multiplexed
immunoﬂuorescence imaging of human tissues and tumors using t-CyCIF
and conventional optical microscopes. Elife 2018;7. http://dx.doi.org/
10.7554/ELIFE.31657.
[177] Zrazhevskiy P, True LD, Gao X. Multicolor multicycle molecular proﬁling with
quantum dots for single-cell analysis. Nat Protoc 2013;8:1852e69. http://
dx.doi.org/10.1038/nprot.2013.112. 2013 810.
[178] Slavov N. Unpicking the proteome in single cells. Science 2020;367:512e3.
http://dx.doi.org/10.1126/science.aaz6695. 80-.
[179] Levy E, Slavov N. Single cell protein analysis for systems biology. Essays
Biochem 2018;62:595e605. http://dx.doi.org/10.1042/EBC20180014.
[180] Nair N, Mei HE, Chen SY, Hale M, Nolan GP, Maecker HT, et al. Mass
cytometry as a platform for the discovery of cellular biomarkers to guide
effective rheumatic disease therapy. Arthritis Res Ther 2015;17. http://
dx.doi.org/10.1186/S13075-015-0644-Z.
[181] Spitzer MH, Nolan GP. Mass cytometry: single cells, many features. Cell
2016;165:780e91. http://dx.doi.org/10.1016/J.CELL.2016.04.019.
[182] Virant-Klun I, Leicht S, Hughes C, Krijgsveld J. Identiﬁcation of maturationspeciﬁc proteins by single-cell proteomics of human oocytes. Mol Cell Proteomics 2016;15:2616e27. http://dx.doi.org/10.1074/MCP.M115.056887.
[183] Sun L, Dubiak KM, Peuchen EH, Zhang Z, Zhu G, Huber PW, et al. Single
cell proteomics using frog (Xenopus laevis) blastomeres isolated from early
stage embryos, which form a geometric progression in protein content.
Anal Chem 2016;88:6653e7. http://dx.doi.org/10.1021/acs.analchem.
6b01921.
[184] Lombard-Banek C, Reddy S, Moody SA, Nemes P. Label-free quantiﬁcation of
proteins in single embryonic cells with neural fate in the cleavage-stage frog
(Xenopus laevis) embryo using capillary electrophoresis electrospray ionization
high-resolution mass spectrometry (CE-ESI-HRMS). Mol Cell Proteomics
2016;15:2756e68. http://dx.doi.org/10.1074/MCP.M115.057760.
[185] Specht H, Harmange G, Perlman DH, Emmott E, Niziolek Z, Budnik B, et al.
Automated sample preparation for high-throughput single-cell proteomics.
bioRxiv 2018 399774. http://dx.doi.org/10.1101/399774.
[186] Budnik B, Levy E, Harmange G, Slavov N. Mass-spectrometry of single
mammalian cells quantiﬁes proteome heterogeneity during cell differentiation. bioRxiv 2018 102681. http://dx.doi.org/10.1101/102681.
[187] Budnik B, Levy E, Harmange G, Slavov N. SCoPE-MS: mass spectrometry of
single mammalian cells quantiﬁes proteome heterogeneity during cell differentiation. Genome Biol 2018;19:1e12. http://dx.doi.org/10.1186/S13059018-1547-5/FIGURES/4.
[188] Specht H, Emmott E, Petelski AA, Huffman RG, Perlman DH, Serra M, et al.
Single-cell proteomic and transcriptomic analysis of macrophage heterogeneity using SCoPE2. Genome Biol 2021;22:1e27. http://dx.doi.org/10.1186/
S13059-021-02267-5/TABLES/2.

[189] Specht H, Emmott E, Petelski AA, Huffman RG, Perlman DH, Serra M, et al.
Single-cell proteomic and transcriptomic analysis of macrophage heterogeneity.
bioRxiv 2020 665307. http://dx.doi.org/10.1101/665307.
[190] Urban PL, Jeﬁmovs K, Amantonico A, Fagerer SR, Schmid T, Mädler S, et al.
High-density micro-arrays for mass spectrometry. Lab Chip 2010;10:3206e
9. http://dx.doi.org/10.1039/C0LC00211A.
[191] Zenobi R. Single-cell metabolomics: analytical and biological perspectives.
Science 2013:342. http://dx.doi.org/10.1126/science.1243259. 80-.
[192] Zhang L, Vertes A. Single-cell mass spectrometry approaches to explore
cellular heterogeneity. Angew Chem Int Ed 2018;57:4466e77. http://
dx.doi.org/10.1002/ANIE.201709719.
[193] Duncan KD, Fyrestam J, Lanekoff I. Advances in mass spectrometry based
single-cell metabolomics. Analyst 2019;144:782e93. http://dx.doi.org/
10.1039/C8AN01581C.
[194] Lanekoff I, Sharma VV, Marques C. Single-cell metabolomics: where are we
and where are we going? Curr Opin Biotechnol 2022;75:102693. http://
dx.doi.org/10.1016/J.COPBIO.2022.102693.
[195] Metwaly A, Haller D. Multi-omics in IBD biomarker discovery: the missing
links. Nat Rev Gastroenterol Hepatol 2019;16:587e8. http://dx.doi.org/
10.1038/S41575-019-0188-9.
[196] Olivier M, Asmis R, Hawkins GA, Howard TD, Cox LA. The need for multiomics biomarker signatures in precision medicine. Int J Mol Sci 2019
2019;20:4781. http://dx.doi.org/10.3390/IJMS20194781. 20, Page 4781.
[197] Ang MY, Low TY, Lee PY, Wan Mohamad, Nazarie WF, Guryev V, Jamal R.
Proteogenomics: from next-generation sequencing (NGS) and mass
spectrometry-based proteomics to precision medicine. Clin Chim Acta
2019;498:38e46. http://dx.doi.org/10.1016/J.CCA.2019.08.010.
[198] Sheynkman GM, Shortreed MR, Cesnik AJ, Smith LM. Proteogenomics:
integrating next-generation sequencing and mass spectrometry to characterize human proteomic variation. Annu Rev Anal Chem 2016;9:521e45.
http://dx.doi.org/10.1146/ANNUREV-ANCHEM-071015-041722.
[199] Weinhold B. Epigenetics: the science of change. Environ Health Perspect
2006;114:A160. http://dx.doi.org/10.1289/EHP.114-A160.
[200] Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics data
integration, interpretation, and its application. Bioinf Biol Insights 2020;14.
http://dx.doi.org/10.1177/1177932219899051.
[201] Colquitt RB, Colquhoun DA, Thiele RH. In silico modelling of physiologic
systems. Best Pract Res Clin Anaesthesiol 2011;25:499e510. http://
dx.doi.org/10.1016/J.BPA.2011.08.006.
[202] Teusink B, Passarge J, Reijenga CA, Esgalhado E, Van Der Weijden CC,
Schepper M, et al. Can yeast glycolysis be understood in terms of in vitro
kinetics of the constituent enzymes? Testing biochemistry. Eur J Biochem
2000;267:5313e29. http://dx.doi.org/10.1046/J.1432-1327.2000.01527.X.
[203] Phair RD, Misteli T. Kinetic modelling approaches to in vivo imaging. Nat Rev
Mol Cell Biol 2001;2:898e907. http://dx.doi.org/10.1038/35103000. 2001
212.
[204] Papoutsakis ET. Equations and calculations for fermentations of butyric acid
bacteria. 20000320 Biotechnol Bioeng 2000;67:813e26. http://dx.doi.org/
10.1002/(sici)1097-0290. 67:6<813::aid-bit17>3.0.co;2-x.
[205] Price ND, Reed JL, Palsson B. Genome-scale models of microbial cells:
evaluating the consequences of constraints. Nat Rev Microbiol 2004;2:886e
97. http://dx.doi.org/10.1038/nrmicro1023.
[206] Wiechert W. 13C metabolic ﬂux analysis. Metab Eng 2001;3:195e206.
http://dx.doi.org/10.1006/mben.2001.0187.
[207] Visser D, Van Der Heijden R, Mauch K, Reuss M, Heijnen S. Tendency
modeling: a new approach to obtain simpliﬁed kinetic models of metabolism
applied to Saccharomyces cerevisiae. Metab Eng 2000;2:252e75. http://
dx.doi.org/10.1006/mben.2000.0150.
[208] Neves AR, Ventura R, Mansour N, Shearman C, Gasson MJ, Maycock C,
et al. Is the glycolytic ﬂux in Lactococcus lactis primarily controlled by the

MOLECULAR METABOLISM 66 (2022) 101635 Ó 2022 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

17

Review

[209]

[210]

[211]

[212]

[213]

[214]

[215]

[216]

[217]

[218]

[219]

[220]

[221]

[222]

[223]
[224]

[225]

18

redox charge? Kinetics of NADþ and NADH pools determined in vivo by
13C NMR. J Biol Chem 2002;277:28088e98. http://dx.doi.org/10.
1074/jbc.M202573200.
Curto R, Voit EO, Sorribas A, Cascante M. Validation and steady-state analysis
of a power-law model of purine metabolism in man. Biochem J 1997;324:
761e75. http://dx.doi.org/10.1042/bj3240761.
Funahashi A, Matsuoka Y, Jouraku A, Morohashi M, Kikuchi N, Kitano H.
CellDesigner 3.5: a versatile modeling tool for biochemical networks. Proc
IEEE 2008;96:1254e65. http://dx.doi.org/10.1109/JPROC.2008.925458.
Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, et al. The
systems biology markup language (SBML): a medium for representation and
exchange of biochemical network models. Bioinformatics 2003;19:524e31.
http://dx.doi.org/10.1093/bioinformatics/btg015.
Moodie S, Le Novère N, Demir E, Mi H, Villéger A. Systems biology graphical
notation: process description language level 1 version 1.3. J Integr Bioinform
2015;12:263. http://dx.doi.org/10.2390/biecoll-jib-2015-263.
Van Hemert JL, Dickerson JA, Valencia A. PathwayAccess: CellDesigner
plugins for pathway databases. Bioinformatics 2011;27:2345e6. http://
dx.doi.org/10.1093/bioinformatics/btq423.
Oki NO, Farcal L, Abdelaziz A, Florean O, Doktorova TY, Exner T, et al. Integrated analysis of in vitro data and the adverse outcome pathway framework for prioritization and regulatory applications: an exploratory case study
using publicly available data on piperonyl butoxide and liver models. Toxicol
Vitro 2019;54:23e32. http://dx.doi.org/10.1016/j.tiv.2018.09.002.
Marín-Hernández A, Gallardo-Pérez JC, Rodríguez-Enríquez S, Encalada R,
Moreno-Sánchez R, Saavedra E. Modeling cancer glycolysis. Biochim Biophys
Acta Bioenerg 2011;1807:755e67. http://dx.doi.org/10.1016/J.BBABIO.
2010.11.006.
Bruck J, Liebermeister W, Klipp E. Exploring the effect of variable enzyme
concentrations in a kinetic model of yeast glycolysis. Genome Inform
2008;20:1e14. http://dx.doi.org/10.1142/9781848163003_0001.
Kanehisa M, Sato Y, Kawashima M. KEGG mapping tools for uncovering
hidden features in biological data. Protein Sci 2022;31:47e53. http://
dx.doi.org/10.1002/PRO.4172.
Olivier BG, Snoep JL. Web-based kinetic modelling using JWS Online. Bioinformatics 2004;20:2143e4. http://dx.doi.org/10.1093/BIOINFORMATICS/
BTH200.
Chelliah V, Juty N, Ajmera I, Ali R, Dumousseau M, Glont M, et al. BioModels:
ten-year anniversary. Nucleic Acids Res 2015;43:D542e8. http://dx.doi.org/
10.1093/NAR/GKU1181.
Costa RS, Veríssimo A, Vinga S. KiMoSys: a web-based repository of
experimental data for KInetic MOdels of biological SYStems. BMC Syst Biol
2014;8. http://dx.doi.org/10.1186/S12918-014-0085-3.
Placzek S, Schomburg I, Chang A, Jeske L, Ulbrich M, Tillack J, et al.
BRENDA in 2017: new perspectives and new tools in BRENDA. Nucleic Acids
Res 2017;45:D380e8. http://dx.doi.org/10.1093/NAR/GKW952.
Pang Z, Chong J, Zhou G, De Lima Morais DA, Chang L, Barrette M, et al.
MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional
insights. Nucleic Acids Res 2021;49:W388e96. http://dx.doi.org/10.1093/
NAR/GKAB382.
Kanehisa M, Sato Y. KEGG Mapper for inferring cellular functions from protein
sequences. Protein Sci 2020;29:28e35. http://dx.doi.org/10.1002/pro.3711.
Berndt N, Egners A, Mastrobuoni G, Vvedenskaya O, Fragoulis A, Dugourd A,
et al. Kinetic modelling of quantitative proteome data predicts metabolic
reprogramming of liver cancer. Br J Cancer 2019 1222 2019;122:233e44.
http://dx.doi.org/10.1038/s41416-019-0659-3.
Kelly RA, Leedale J, Harrell A, Beard DA, Randle LE, Chadwick AE, et al.
Modelling the impact of changes in the extracellular environment on the
cytosolic free NADþ/NADH ratio during cell culture. PLoS One 2018;13:
e0207803. http://dx.doi.org/10.1371/JOURNAL.PONE.0207803.

[226] Schoeberl B, Eichler-Jonsson C, Gilles ED, Muüller G. Computational
modeling of the dynamics of the MAP kinase cascade activated by surface
and internalized EGF receptors. Nat Biotechnol 2002;20:370e5. http://
dx.doi.org/10.1038/NBT0402-370.
[227] Markevich NI, Hoek JB, Kholodenko BN. Signaling switches and bistability
arising from multisite phosphorylation in protein kinase cascades. J Cell
Biol 2004;164:353e9. http://dx.doi.org/10.1083/JCB.200308060.
[228] Huang CYF, Ferrell JE. Ultrasensitivity in the mitogen-activated protein kinase
cascade. Proc Natl Acad Sci U S A 1996;93:10078e83. http://dx.doi.org/
10.1073/PNAS.93.19.10078.
[229] Hoffmann A, Levchenko A, Scott ML, Baltimore D. The IkappaB-NF-kappaB
signaling module: temporal control and selective gene activation. Science
2002;298:1241e5. http://dx.doi.org/10.1126/SCIENCE.1071914.
[230] Bhalla US, Ram PT, Iyengar R. MAP kinase phosphatase as a locus of
ﬂexibility in a mitogen-activated protein kinase signaling network. Science
2002;297:1018e23. http://dx.doi.org/10.1126/SCIENCE.1068873.
[231] Aldridge BB, Burke JM, Lauffenburger DA, Sorger PK. Physicochemical
modelling of cell signalling pathways. Nat Cell Biol 2006;8:1195e203. http://
dx.doi.org/10.1038/NCB1497.
[232] Maier K, Hofmann U, Reuss M, Mauch K. Dynamics and control of the central
carbon metabolism in hepatoma cells. BMC Syst Biol 2010;4:1e28. http://
dx.doi.org/10.1186/1752-0509-4-54/TABLES/5.
[233] Yarmush G, Santos L, Yarmush J, Koundinyan S, Saleem M, Nativ NI, et al.
Metabolic ﬂux distribution during defatting of steatotic human hepatoma
(HepG2) cells. Metabolism 2016 2016;6:1. http://dx.doi.org/10.3390/
METABO6010001. Vol 6, Page 1.
[234] De Gelder J, De Gussem K, Vandenabeele P, Moens L. Reference database of
Raman spectra of biological molecules. J Raman Spectrosc 2007;38:1133e
47. http://dx.doi.org/10.1002/JRS.1734.
[235] Bonnier F, Knief P, Lim B, Meade AD, Dorney J, Bhattacharya K, et al. Imaging live cells grown on a three dimensional collagen matrix using Raman
microspectroscopy. Analyst 2010;135:3169e77. http://dx.doi.org/10.1039/
c0an00539h.
[236] Boydston-White S, Romeo M, Chernenko T, Regina A, Miljkovic M, Diem M.
Cell-cycle-dependent variations in FTIR micro-spectra of single proliferating
HeLa cells: principal component and artiﬁcial neural network analysis. Biochim Biophys Acta Biomembr 2006;1758:908e14. http://dx.doi.org/
10.1016/j.bbamem.2006.04.018.
[237] Matthäus C, Boydston-White S, Miljkovic M, Romeo M, Diem M. Raman and
infrared microspectral imaging of mitotic cells. Appl Spectrosc 2006;60:1e8.
http://dx.doi.org/10.1366/000370206775382758.
[238] Short KW, Carpenter S, Freyer JP, Mourant JR. Raman spectroscopy detects
biochemical changes due to proliferation in mammalian cell cultures. Biophys
J 2005;88:4274e88. http://dx.doi.org/10.1529/biophysj.103.038604.
[239] Ami D, Neri T, Natalello A, Mereghetti P, Doglia SM, Zanoni M, et al. Embryonic stem cell differentiation studied by FT-IR spectroscopy. Biochim
Biophys Acta Mol Cell Res 2008;1783:98e106. http://dx.doi.org/10.1016/
j.bbamcr.2007.08.003.
[240] Notingher I, Bisson I, Bishop AE, Randle WL, Polak JMP, Hench LL. In situ
spectral monitoring of mRNA translation in embryonic stem cells during
differentiation in vitro. Anal Chem 2004;76:3185e93. http://dx.doi.org/
10.1021/ac0498720.
[241] Pavillon N, Hobro AJ, Akira S, Smith NI. Noninvasive detection of macrophage
activation with single-cell resolution through machine learning. Proc Natl
Acad Sci U S A 2018;115:E2676e85. http://dx.doi.org/10.1073/pnas.
1711872115.
[242] Meade AD, Lyng FM, Knief P, Byrne HJ. Growth substrate induced functional
changes elucidated by FTIR and Raman spectroscopy in in-vitro cultured
human keratinocytes. Anal Bioanal Chem 2007;387:1717e28. http://
dx.doi.org/10.1007/s00216-006-0876-5.

MOLECULAR METABOLISM 66 (2022) 101635 Ó 2022 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

[243] Gasparri F, Muzio M. Monitoring of apoptosis of HL60 cells by fouriertransform infrared spectroscopy. Biochem J 2003;369:239e48. http://
dx.doi.org/10.1042/BJ20021021.
[244] Liu KZ, Jia L, Kelsey SM, Newland AC, Mantsch HH. Quantitative determination of apoptosis on leukemia cells by infrared spectroscopy. Apoptosis
2001;6:269e78. http://dx.doi.org/10.1023/A:1011383408381.
[245] Gargotti M, Efeoglu E, Byrne HJ, Casey A. Raman spectroscopy detects
biochemical changes due to different cell culture environments in live cells
in vitro. Anal Bioanal Chem 2018;410:7537e50. http://dx.doi.org/10.1007/
s00216-018-1371-5.
[246] Bonnier F, Knief P, Meade AD, Dorney J, Bhattacharya K, Lyng FM, et al.
Collagen matrices as an improved model for in vitro study of live cells using
Raman microspectroscopy. Clin. Biomed. Spectrosc. Imaging II, 24th May
2011;8087. http://dx.doi.org/10.1117/12.889872. 80870F-80870F e 10.
[247] Meade AD, Clarke C, Draux F, Sockalingum GD, Manfait M, Lyng FM, et al.
Studies of chemical ﬁxation effects in human cell lines using Raman
microspectroscopy. Anal Bioanal Chem 2010;396:1781e91. http://
dx.doi.org/10.1007/S00216-009-3411-7/TABLES/2.
[248] Dorney J, Bonnier F, Garcia A, Casey A, Chambers G, Byrne HJ. Identifying
and localizing intracellular nanoparticles using Raman spectroscopy. Analyst
2012;137:1111e9. http://dx.doi.org/10.1039/c2an15977e.
[249] Matthäus C, Chernenko T, Newmark JA, Warner CM, Diem M. Label-free
detection of mitochondrial distribution in cells by nonresonant Raman
microspectroscopy. Biophys J 2007;93:668e73. http://dx.doi.org/10.1529/
biophysj.106.102061.
[250] van Manen H-J, Kraan YM, Roos D, Otto C. Single-cell Raman and ﬂuorescence microscopy reveal the association of lipid bodies with phagosomes in
leukocytes. Proc Natl Acad Sci U S A 2005;102:10159e64. http://dx.doi.org/
10.1073/pnas.0502746102.
[251] Farhane Z, Bonnier F, Casey A, Byrne HJ. Raman micro spectroscopy for
in vitro drug screening: subcellular localisation and interactions of doxorubicin. Analyst 2015;140:4212e23. http://dx.doi.org/10.1039/c5an00256g.
[252] Theophilou G, Paraskevaidi M, Lima KM, Kyrgiou M, Martin-Hirsch PL,
Martin FL. Extracting biomarkers of commitment to cancer development:
potential role of vibrational spectroscopy in systems biology. Expert Rev
Mol Diagn 2015;15:693e713. http://dx.doi.org/10.1586/14737159.2015.
1028372.
[253] Paraskevaidi M, Matthew BJ, Holly BJ, Hugh BJ, Thulya CPV, Loren C, et al.
Clinical applications of infrared and Raman spectroscopy in the ﬁelds of
cancer and infectious diseases. Appl Spectrosc Rev 2021;56:804e68. http://
dx.doi.org/10.1080/05704928.2021.1946076.
[254] Szafraniec E, Majzner K, Farhane Z, Byrne HJ, Lukawska M, Oszczapowicz I,
et al. Spectroscopic studies of anthracyclines: structural characterization and
in vitro tracking. Spectrochim Acta Part A Mol Biomol Spectrosc 2016;169:
152e60. http://dx.doi.org/10.1016/j.saa.2016.06.035.
[255] Farhane Z, Bonnier F, Byrne HJ. Monitoring doxorubicin cellular uptake and
trafﬁcking using in vitro Raman microspectroscopy: short and long time
exposure effects on lung cancer cell lines. Anal Bioanal Chem 2017;409:
1333e46. http://dx.doi.org/10.1007/s00216-016-0065-0.
[256] Farhane Z, Bonnier F, Byrne HJ. An in vitro study of the interaction of the
chemotherapeutic drug Actinomycin D with lung cancer cell lines using
Raman micro-spectroscopy. J Biophot 2018;11. http://dx.doi.org/10.1002/
jbio.201700112.
[257] Farhane Z, Bonnier F, Howe O, Casey A, Byrne HJ. Doxorubicin kinetics and
effects on lung cancer cell lines using in vitro Raman micro-spectroscopy:
binding signatures, drug resistance and DNA repair. J Biophot 2018;11.
http://dx.doi.org/10.1002/jbio.201700060.
[258] Efeoglu E, Keating M, McIntyre J, Casey A, Byrne HJ. Determination of
nanoparticle localisation within subcellular organelles in vitro using Raman
spectroscopy. Anal Methods 2015;7:10000e17. http://dx.doi.org/10.1039/
c5ay02661j.

[259] Efeoglu E, Casey A, Byrne HJ. In vitro monitoring of time and dose dependent
cytotoxicity of aminated nanoparticles using Raman spectroscopy. Analyst
2016;141:5417e31. http://dx.doi.org/10.1039/c6an01199c.
[260] Efeoglu E, Casey A, Byrne HJ. Determination of spectral markers of cytotoxicity and genotoxicity using in vitro Raman microspectroscopy: cellular
responses to polyamidoamine dendrimer exposure. Analyst 2017;142:3848e
56. http://dx.doi.org/10.1039/c7an00969k.
[261] Efeoglu E, Maher MA, Casey A, Byrne HJ. Toxicological assessment of nanomaterials: the role of in vitro Raman microspectroscopic analysis. Anal Bioanal
Chem 2018;410:1631e46. http://dx.doi.org/10.1007/s00216-017-0812-x.
[262] Xu J, Zhu D, Ibrahim AD, Allen CCR, Gibson CM, Fowler PW, et al. Raman
deuterium isotope probing reveals microbial metabolism at the single-cell
level. Anal Chem 2017;89:13305e12. http://dx.doi.org/10.1021/acs.analchem.7b03461.
[263] Zhang L, Shi L, Shen Y, Miao Y, Wei M, Qian N, et al. Spectral tracing of
deuterium for imaging glucose metabolism. Nat Biomed Eng 2019;3:402.
http://dx.doi.org/10.1038/S41551-019-0393-4.
[264] Noothalapati H, Shigeto S. Exploring metabolic pathways in vivo by a
combined approach of mixed stable isotope-labeled Raman microspectroscopy and multivariate curve resolution analysis. Anal Chem
2014;86:7828e34.
http://dx.doi.org/10.1021/AC501735C/SUPPL_FILE/
AC501735C_SI_001.PDF.
[265] Li M, Huang WE, Gibson CM, Fowler PW, Jousset A. Stable isotope probing
and Raman spectroscopy for monitoring carbon ﬂow in a food chain and
revealing metabolic pathway. Anal Chem 2013;85:1642e9. http://dx.doi.org/
10.1021/AC302910X/SUPPL_FILE/AC302910X_SI_003.GIF.
[266] Noothalapati Venkata HN, Shigeto S. Stable isotope-labeled Raman imaging
reveals dynamic proteome localization to lipid droplets in single ﬁssion yeast
cells. Chem Biol 2012;19:1373e80. http://dx.doi.org/10.1016/J.CHEMBIOL.
2012.08.020.
[267] Weber F, Zaliznyak T, Edgcomb VP, Taylor GT. Using stable isotope probing
and Raman microspectroscopy to measure growth rates of heterotrophic
bacteria. Appl Environ Microbiol 2021;87. http://dx.doi.org/10.1128/
AEM.01460-21/SUPPL_FILE/AEM.01460-21-S0001.PDF.
[268] Ryan SM, Frías JM, Wang X, Sayers CT, Haddleton DM, Brayden DJ. PK/PD
modelling of comb-shaped PEGylated salmon calcitonin conjugates of
differing molecular weights. J Contr Release 2011;149:126e32. http://
dx.doi.org/10.1016/j.jconrel.2010.10.004.
[269] Kitano H. Systems biology: a brief overview. Science 2002;295:1662e4.
http://dx.doi.org/10.1126/science.1069492. 80-.
[270] Steuer R, Junker BH. Computational models of metabolism: stability and
regulation in metabolic networks. Adv Chem Phys 2008;142:105. http://
dx.doi.org/10.1002/9780470475935.ch3. 251.
[271] Mukherjee R, Verma T, Nandi D, Umapathy S. Understanding the effects of
culture conditions in bacterial growth: a biochemical perspective using
Raman microscopy. J Biophot 2020;13. http://dx.doi.org/10.1002/JBIO.
201900233.
[272] Mair T, Zimányi L, Khoroshyy P, Müller A, Müller SC. Analysis of the oscillatory kinetics of glycolytic intermediates in a yeast extract by FT-IR spectroscopy. Biosystems 2006;83:188e94. http://dx.doi.org/10.1016/J.
BIOSYSTEMS.2005.05.016.
[273] Poonprasartporn A, Chan KLA. Live-cell ATR-FTIR spectroscopy as a novel
bioanalytical tool for cell glucose metabolism research. Biochim Biophys Acta
Mol Cell Res 2021;1868:119024. http://dx.doi.org/10.1016/j.bbamcr.2021.
119024.
[274] Poonprasartporn A, Chan KLA. Label-free study of intracellular glycogen level
in metformin and resveratrol-treated insulin-resistant HepG2 by live-cell FTIR
spectroscopy. Biosens Bioelectron 2022;212:114416. http://dx.doi.org/
10.1016/J.BIOS.2022.114416.
[275] Pleitez MA, Khan AA, Soldà A, Chmyrov A, Reber J, Gasparin F, et al. Labelfree metabolic imaging by mid-infrared optoacoustic microscopy in living

MOLECULAR METABOLISM 66 (2022) 101635 Ó 2022 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

19

Review

[276]

[277]

[278]

[279]
[280]

[281]

[282]

[283]

20

cells. Nat Biotechnol 2020;38:293e6. http://dx.doi.org/10.1038/s41587019-0359-9.
Cheng JX, Xie XS. Vibrational spectroscopic imaging of living systems: an
emerging platform for biology and medicine. Science 2015:350. http://
dx.doi.org/10.1126/SCIENCE.AAA8870. 80-.
Liao CS, Huang KC, Hong W, Chen J, Caroline K, Eakins G, et al. Stimulated
Raman spectroscopic imaging by microsecond delay-line tuning. Opt. InfoBase Conf. Pap. 2014. http://dx.doi.org/10.1364/ACPC.2016.ATH2K.5.
Hong W, Liao C-S, Zhao H, Younis W, Zhang Y, Seleem MN, et al. In situ
detection of a single bacterium in complex environment by hyperspectral
CARS imaging. Wiley Online Libr 2016;1:513e7. http://dx.doi.org/10.1002/
slct.201600166.
Zhang C, Cheng JX. Perspective: coherent Raman scattering microscopy, the
future is bright. APL Photonics 2018;3. http://dx.doi.org/10.1063/1.5040101.
Minamikawa T, Murakami Y, Matsumura N, Niioka H, Fukushima S, Araki T,
et al. Photo-induced cell damage analysis for single-and multifocus coherent
anti-Stokes Raman scattering microscopy. J Spectrosc 2017;2017. http://
dx.doi.org/10.1155/2017/5725340.
Jaumot J, Gargallo R, De Juan A, Tauler R. A graphical user-friendly interface
for MCR-ALS: a new tool for multivariate curve resolution in MATLAB. Chemometr Intell Lab Syst 2005;76:101e10. http://dx.doi.org/10.1016/
j.chemolab.2004.12.007.
Singular Value decomposition - MATLAB & simulink - MathWorks United
Kingdom
n.d.
https://uk.mathworks.com/help/symbolic/singular-valuedecomposition.html.
Males P, Brkljaca Z, Crnolatac I, Bakaric D. Application of MCR-ALS with EFA on
FT-IR spectra of lipid bilayers in the assessment of phase transition temperatures: potential for discernment of coupled events. Colloids Surf B Biointerfaces
2021;201:111645. http://dx.doi.org/10.1016/j.colsurfb.2021.111645.

[284] Perez-Guaita D, Quintas G, Farhane Z, Tauler R, Byrne HJ. Data mining
Raman microspectroscopic responses of cells to drugs in vitro using multivariate curve resolution-alternating least squares. Talanta 2020;208. http://
dx.doi.org/10.1016/j.talanta.2019.120386. 0e21.
[285] Perez-Guaita D, Chrabaszcz K, Malek K, Byrne HJ. Multimodal vibrational
studies of drug uptake in vitro: is the whole greater than the sum of their
parts? J Biophot 2020;13. http://dx.doi.org/10.1002/jbio.202000264.
[286] Vernooij RR, Joshi T, Horbury MD, Graham B, Izgorodina EI, Stavros VG, et al.
Spectroscopic studies on photoinduced reactions of the anticancer prodrug,
trans,trans,trans-[Pt(N3)2(OH)2(py)2]. Chem Eur J 2018;24:5790e803.
http://dx.doi.org/10.1002/chem.201705349.
[287] Zhang C, Zhang D, Cheng JX. Https://DoiOrg/101146/Annurev-Bioeng071114-040554. Coherent Raman scattering microscopy in biology and
medicine, vol. 17; 2015. http://dx.doi.org/10.1146/ANNUREV-BIOENG071114-040554. 415e45.
[288] Dazzi A, Policar C. AFM-IR: photothermal infrared nanospectroscopy: application to cellular imaging. Biointerface charact. By adv. IR spectrosc. Elsevier
2011:245e78. http://dx.doi.org/10.1016/B978-0-444-53558-0.00009-6.
[289] Mathurin J, Deniset-Besseau A, Bazin D, Dartois E, Wagner M, Dazzi A.
Photothermal AFM-IR spectroscopy and imaging: status, challenges, and
trends. J Appl Phys 2022;131:010901. http://dx.doi.org/10.1063/5.0063902.
[290] Wissmeyer G, Pleitez MA, Rosenthal A, Ntziachristos V. Looking at sound:
optoacoustics with all-optical ultrasound detection. Light Sci Appl 2018;7.
http://dx.doi.org/10.1038/S41377-018-0036-7.
[291] Kansiz M, Prater C, Dillon E, Lo M, Anderson J, Marcott C, et al. Optical
photothermal infrared microspectroscopy with simultaneous Raman e a new
non-contact failure analysis technique for identiﬁcation of <10 mm organic
contamination in the hard drive and other electronics industries. Micros Today
2020;28:26. http://dx.doi.org/10.1017/S1551929520000917.

MOLECULAR METABOLISM 66 (2022) 101635 Ó 2022 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

